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Resumo 
 
 
Os objetivos deste estudo são: 
1) Estudar  e comparar a diversidade filogenética de cepas de Fusarium spp  
isoladas de casos de ceratites infecciosas no Sul da Flórida – Estados Unidos da América 
(EUA)  por meio de identificação por genotipagem e métodos microbiológicos de análise 
fenotípica; 
 2) Analisar as espécies de Fusarium  isoladas de ceratites  no Sul da Flórida – 
EUA identificadas por genotipagem, seus perfis de susceptibilidade in vitro a antifúngicos, 
bem como os dados clínicos dos pacientes;  
3) Estudar  e comparar a diversidade filogenética de cepas de Fusarium spp  
isoladas de casos de ceratites infecciosas no Brasil, identificadas  por genotipagem e 
métodos microbiológicos de análise fenotípica, os resultados dos testes de  
susceptibilidade in vitro a antifúngicos e os dados clínicos dos pacientes; 
4) Comparação dos dados de identificação  de cepas de Fusarium spp  de 
portadores de ceratites infecciosas nos EUA e no Brasil, avaliando também a  
susceptibilidade a antifúngicos e os dados clínicos dos pacientes estudados. 
 
Para a identificação das cepas provenientes de casos de ceratite por Fusarium spp 
nos EUA e no Brasil, utilizou-se a análise de sequência de DNA da região Internal 
Transcribed Spacer (ITS), assim como a classificação morfológica pela microbiologia 
tradicional, com o estudo macro e microscópico das cepas. Testes por microdiluição em 
caldo foram efetuados para obter-se os perfis de susceptibilidade in vitro das cepas 
estudadas aos antifúngicos natamicina, anfotericina B e voriconazol. Os prontuários dos 
respectivos pacientes foram analisados e suas características clínicas comparadas aos 
dados de genotipagem e testes de susceptibilidade a antifúngicos. 
Nos EUA 58 isolados de ceratites foram classificados por genotipagem em: 
Fusarium solani (75%), F. oxysporum (16%), F. incarnatum-equiseti (5%), F. dimerum 
(2%) e  um Fusarium spp  (2%)  que não  foi classificado  dentro de nenhum  complexo de  
xiv 
 espécies. Isolados de F. solani tiveram valores de MIC90 de voriconazol significativamente 
mais elevados do que os F. não-solani (16 e 4ug/ml, respectivamente). Os pacientes com 
isolados de F. solani também exibiram um tempo para cura mais longo (65 vs 40 dias), 
uma pior acuidade visual final média (20/118 vs 20/36), e um maior necessidade de 
ceratoplastia terapêutica (7 vs 0 cirurgias), quando comparados aos que tiveram infecções 
causadas por F. não-solani. O uso de lentes de contato foi o fator de risco mais frequente 
entre os pacientes deste estudo (66%). 
No Brasil os 41 isolados de ceratites foram classificados genotipicamente em: F. 
solani (88%), F. oxysporum (5%), F. dimerum (2%) e dois Fusarium spp (5%) que não 
foram classificados dentro de nenhum complexo de espécies. O atraso para o início do 
tratamento foi de 19 dias em média, e o tempo para a cura foi em média 107 dias. A 
acuidade visual final dos pacientes variou de 20/20 a percepção de luz e foi em média 
20/800 (LogMAR 1,6). A história de trauma foi o fator de risco mais frequente, estando 
presente em 20 pacientes (50%). Ceratoplastia terapêutica foi necessária em 22 pacientes 
(54%).  
A anfotericina B teve os menores valores de MIC90 (2ug/ml) tanto no Brasil como 
nos EUA. Voriconazol teve os maiores valores (16ug/ml) em ambos países. Os isolados 
foram um pouco mais resistentes a natamicina no Brasil (8 vs 4 ug/ml nos EUA), e neste 
país também houve uma associação entre cepas com maior MIC para natamicina e maior 
necessidade de ceratoplastia terapêutica. 
 Pela  comparação dos  resultados de identificação, susceptibilidade a antifúngicos 
e dados clínicos, obtidos de casos de ceratites por Fusarium spp nos EUA e no Brasil, é 
possivel concluir-se que: as acuidades visuais inicial e final foram piores no Brasil; um 
maior número de homens e trauma estavam presentes no estudo brasileiro ao invés de 
mulheres e uso de lentes de contato (LC) nos EUA; um maior número de ceratoplastias 
terapêuticas foram necessárias no Brasil; e um maior tempo para o diagnóstico e para a 
cura foram encontrados no Brasil. 
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1. INTRODUÇÃO 
 
Após o recente surto global de ceratites por Fusarium spp associadas ao uso de 
lentes de contato (2005-2006)1, tem havido um interesse renovado e um foco importante 
de pesquisas sobre epidemiologia, diagnóstico, classificação e tratamento de ceratites 
fúngicas.  
A incidência de ceratite por Fusarium spp aumentou dramaticamente ao longo das 
últimas quatro décadas, sendo responsável por até 62% dos casos de ceratite infecciosa 
em climas tropicais.2-10 Esta crescente incidência é multifatorial e acredita-se ser devida a 
uma maior conscientização e mudanças no perfil de fatores de risco em toda a população 
mundial, incluindo um aumento do uso de esteróides tópicos e agentes antimicrobianos, 
assim como um aumento no número de procedimentos cirúrgicos, uso de lentes de 
contato, trauma ocular, doenças crônicas da superfície ocular, e pacientes 
imunocomprometidos por AIDS e transplantes de órgãos.7,11-14 
O Brasil, como outros países tendo uma parte importante do território na zona 
tropical, tem uma quantidade significativa de casos de ceratite fúngica, variando de 11 a 
56% de todas as culturas positivas.15,16 Em países como China e Índia, os fungos podem 
ser a etiologia de até 62% dos casos de ceratite infecciosa.4,7 Entre os fungos causadores 
de ceratite, Fusarium spp é no geral o mais prevalente. Estudos mostram 45-67% das 
ceratites fúngicas no Brasil sendo causadas por esse microrganismo.6,12,15-17 Entre as 
espécies de Fusarium que são patogênicas para o olho, F. solani é o mais comum (até 
91% dos isolados)6, seguido de outras espécies como F. oxysporum e F. dimerum.18,19 
O diagnóstico etiológico de ceratites fúngicas é um desafio devido às limitações 
dos métodos de microscopia e cultura. Técnicas microbiológicas serviram durante muito 
tempo como o padrão ouro no diagnóstico de ceratites fúngicas. Tais técnicas são 
capazes de diferenciar entre as leveduras e os fungos filamentosos que causam ceratite. 
Embora altamente precisas no gênero (Fusarium, Aspergillus, Candida, etc), a 
identificação morfológica de isolados de Fusarium ao nível de espécie (F. solani, F. 
oxysporum, etc) é problemático e inconsistente, devido ao grande grau de variabilidade 
morfológica demonstrado em diferentes estágios do crescimento.19,20 Além disto, métodos 
baseados em cultura são trabalhosos e demorados, exigindo microbiologistas 
 2 
especialmente treinados, para identificar os isolados ao nível de espécie, normalmente 
demorando 3 a 7 dias após a identificação do gênero. Identificação com base no exame 
histopatológico da córnea permite um diagnóstico rápido, mas tem uma sensibilidade 
muito variável e é menos eficaz na diferenciação a nível de espécie.9 O atraso na 
identificação do agente etiológico e início do tratamento apropriado, resulta em um 
aumento da morbidade ocular. Técnicas de biologia molecular têm sido sugeridas para 
resolver estas limitações e podem melhorar significativamente os recursos de diagnóstico, 
bem como o prognóstico dos pacientes. 11-14,18-23 
O crescente número de relatórios de Fusarium como um patógeno humano, têm 
gerado um interesse em encontrar uma método mais rápido, preciso e consistente para o 
diagnóstico e classificação deste organismo. Felizmente, várias técnicas moleculares, 
incluindo a reação em cadeia da polimerase (PCR), real-time PCR, Luminex e tecnologia 
de Microarrays têm-se mostrado uma promessa, mostrando resultados promissores tanto 
em humanos quanto em modelos animais experimentais.1,11-14,18-23 Estudos de 
genotipagem recentes mostraram que os métodos baseados na sequência de DNA são 
úteis para identificação de espécies de Fusarium.1,20,24,25 Uma identificação precisa é 
importante não só para promover o entendimento do espectro de fusaria que são 
patogênicos para os olhos, mas importante também na obtenção de  informação de 
prognóstico e terapia para os pacientes. 
Muitos genes diferentes proporcionaram a base para o desenvolvimento de 
técnicas moleculares de identificação, incluindo RNA ribossomal (rRNA), o fator de 
alongamento  (EF-1alfa), a subunidade da RNA polimerase II (RPB2), e os domínios 
D1/D2 da subunidade nuclear maior (LSU).1,24,26,27 Muitos estudos de genotipagem de 
fungos têm contado com o complexo de genes rRNA para a identificação rápida de 
espécies.14,18,28-33 Esta família de genes ribossomais compreende quatro rRNA genes: o 
26 a 28S, 18S, 5.8S e 5S genes, que estão separados pela a região espaçadora 
intergênica (IGS). Os genes de rRNA são altamente conservados e as regiões 
espaçadoras internas de transcrição (ITS) são tipicamente variáveis e ricas em sítios 
informativos, daí a sua utilidade para classificação filogenética.31,32 Além disto, o fato dos 
rRNA genes serem multicópia, ou seja, várias cópias destes genes estão presentes dentro 
da mesma célula, aumenta a sensibilidade do PCR que tem estes genes como alvo. 
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Embora a capacidade da região ITS para diferenciar espécies de importância 
médica no gênero Fusarium tenha sido demonstrada, novos complexos de espécies têm 
sido relatados, e nenhum estudo foi realizado para examinar completamente a utilidade da 
variabilidade alélica destes genes para diferenciar espécies de Fusarium de fontes 
oculares em um nível clinicamente relevante. 
A questão permanece: é clinicamente importante identificar ao nível de espécie as 
cepas de Fusarium que causam ceratite? Relatórios recentes sugerem que fungos 
filamentosos possuem uma susceptibilidade in vitro espécie-específica aos agentes 
antifúngicos.26-28 Dentro do gênero Fusarium e entre as espécies patogênicas para o olho, 
no entanto, estes perfis de susceptibilidade antifúngica ainda não foram firmemente 
estabelecidas.29,30 Além disto, embora a etiologia e epidemiologia da ceratite por Fusarium 
sejam alvo freqüente de estudos,4-6,31,32 muito pouco foi revelado sobre as diferenças nas 
características clínicas e resultados associados com infecções causadas por espécies 
específicas. 
Há uma falta de informação epidemiológica e clínica no tratamento de úlceras 
fúngicas. O tratamento das ceratomicoses ainda é largamente empírico, sem um 
consenso sobre o papel dos testes de susceptibilidade na escolha da terapia mais 
adequada. Alguns estudos mostraram que existe uma correlação entre a susceptibilidade 
a antibióticos e resultados clínicos em ceratites bacterianas.34-36 Novos estudos estão 
começando a mostrar que a relação entre a susceptibilidade aos antifúngicos e o 
prognóstico clínico também existe em casos de ceratites fúngicas.37-39 
Informações sobre susceptibilidade a antifúngicos e correlação com os resultados 
clínicos ainda é limitada, especialmente no Brasil. Esta informação será muito útil para 
melhorar as estratégias de tratamento para ceratites por Fusarium spp, o principal agente 
etiológico de ceratites fúngicas no Brasil e vários outros países no mundo. 1,4-13,15-17 
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1.1 Objetivos 
 
1. Estudar a diversidade filogenética de 58 cepas genotipadas de tecidos oculares, lentes 
de contato e estojos de lentes de pacientes com ceratite por Fusarium spp no Sul da 
Flórida – EUA, comparando com métodos tradicionais de microbiologia no diagnóstico 
destas ceratites. 
Utility of Molecular Sequence Analysis of the ITS rRNA Region for Identification of 
Fusarium spp. from Ocular Sources 
Invest Ophthalmol Vis Sci. 2009;50:2230–2236. 
 
2. Comparar as espécies das 58 cepas de Fusarium anteriormente genotipadas,  
analisando seus perfis de susceptibilidade in vitro a antifúngicos e suas características 
clínicas. 
Fusarium keratitis: genotyping, in vitro susceptibility and clinical outcomes 
Cornea 2013. No prelo. 
 
3. Identificar por genotipagem 41 cepas de ceratite por Fusarium spp no Brasil, testar sua 
susceptibilidade in vitro e correlacionar seus dados clínicos. 
Fusarium keratitis in Brazil: genotyping, in vitro susceptibilities and clinical 
outcomes 
Clin Ophthalmol. Manuscrito aceito para publicação. 
 
4. Comparar os dados de identificação, susceptibilidade a antifúngicos e dados clínicos, 
obtidos de ceratites por Fusarium spp nos EUA e no Brasil. 
Fusarium keratitis in Brazil and United States: comparison of laboratorial analysis 
and clinical outcomes 
Artigo em finalização para envio a publicação. 
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2. CONCLUSÕES 
 
1. A região ITS demonstrou-se capaz de classificar as cepas em diferentes complexos de 
espécies. O diagnóstico por genotipagem também demonstrou-se mais específico e 
rápido do que o feito utilizando-se a microbiologia tradicional em ambos os países. 
 
2. A espécie F. solani demonstrou ser a mais patogênica dentro do gênero Fusarium, com 
pior acuidade visual final média e maior necessidade de ceratoplastia terapêutica nos 
EUA. Esta espécie também foi mais resistente ao voriconazol quando comparada às 
demais espécies neste mesmo país. 
 
3. O prognóstico visual dos pacientes no Brasil foi reservado (AV final média = 20/800), e 
mais da metade (54%) dos pacientes tiveram a necessidade de ceratoplastia terapêutica. 
O antifúngico com a maior eficácia in vitro foi a anfotericina B. Houve uma associação 
entre maior resistência in vitro à natamicina e maior necessidade de ceratoplastia 
terapêutica. 
 
4. A acuidade visual inicial e final foram piores no Brasil que nos EUA; um maior número 
de homens e trauma estavam presentes no estudo brasileiro contra mulheres e uso de LC 
nos EUA; um maior número de ceratoplastias terapêuticas foram necessárias no Brasil; 
um maior tempo para o diagnóstico e para cura foram encontrados no Brasil. 
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3. ARTIGOS 
 
3.1 Utility of Molecular Sequence Analysis of the ITS rRNA Region for Identification 
of Fusarium spp. from Ocular Sources 
 
Rafael A. Oechsler, MD; Michael R. Feilmeier, MD; Dolena R. Ledee, PhD; Darlene Miller, 
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ABSTRACT 
Purpose: 
Fungal ocular infections cause significant ocular morbidity, particularly when the diagnosis 
and treatment are delayed. Accurate morphological identification of Fusarium spp. beyond 
the genus is timely and insensitive. It was the purpose of this study to examine the 
usefulness of the nuclear ribosomal RNA (rRNA) internal transcribed spacer regions (ITS1 
and 2) to detect and differentiate Fusarium spp. responsible for ocular infections.  
Methods: 
Fifty-eight archived isolates from ocular sources of 52 patients diagnosed with Fusarium 
keratitis at the Bascom Palmer Eye Institute (BPEI, Miami, FL) from April 2000 to May 
2007 were analyzed.  The archived samples, which were initially classified according to 
morphological characteristics, were analyzed by DNA sequence data generated from the 
ITS regions of the rRNA genes.  
Results: 
15 distinct sequences were identified among the 58 isolates. Sequence analysis identified 
the isolates as Fusarium solani (75%), F. oxysporum (16%), F. incarnatum-equiseti (5%), 
F. dimerum (2%) and one Fusarium spp (2%) that was not classified within any species 
complex. Species identification based on sequence data correlated well with the 
morphological classification when performed by a mycology reference laboratory, but a 
higher rate of mismatch was observed based on identification by a non-reference 
laboratory. 
Conclusions:  
The majority of the isolates of Fusarium ocular infections belong to the F. solani or F. 
oxysporum species complexes. Morphological classification to the species level yielded 
inconsistent results at a general microbiology laboratory.  In contrast, the sequence 
variation within the ITS region allowed reliable and faster discrimination of the isolates at 
both the genus and species level. 
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INTRODUCTION 
 
Fungal corneal ulcers are a prevalent cause of ocular morbidity throughout the 
world1, and the incidence has increased significantly over the last 3 decades2,3 largely as 
the result of increases in patient risk factor profiles. The etiology of infectious keratitis is 
variable and largely dependent upon geographic and climatic variables, as well as patient 
risk factor profiles. Fungal organisms are the etiologic agent in 1.2% to 62% of infectious 
keratitis case, and are significantly more common in tropical and subtropical regions.4-8  
Fusarium is the most common genus isolated in cases of fungal keratitis in tropical and 
subtropical regions, where they represent as much as 45% to 73% of fungal keratitis 
cases2-4,7,9.  
Diagnosis of fungal keratitis is challenging due to limitations in culture and 
microscopy based methods of identification.   Culture based methods are labor intensive 
and time consuming, requiring specially trained mycologists to properly identify isolates at 
the species level, typically yielding positive results 3-7 days after initial presentation. 
Identification based on histopathological examination of corneal scrapings allows for a 
rapid diagnosis of a fungal infection, but has highly variable sensitivity and is less effective 
at differentiating isolates at the species level.8  This delay in identification of the etiologic 
agent and initiation of appropriate antimicrobial coverage undoubtedly results in increased 
ocular morbidity.  Molecular diagnostic techniques have been suggested to address these 
limitations, and can significantly improve our diagnostic capabilities as well as patient 
outcomes in the future. 
The increasing reports of Fusarium as a human pathogen in ocular infections have 
generated an interest in finding a more rapid, accurate and consistent method for 
diagnosis and classification.  Fortunately, numerous molecular techniques, including PCR-
based technology and microarray technology have shown promise in offering a solution in 
both human and animal experimental models.10-20 Recent genotyping studies have shown 
that DNA sequence-based methods are useful for species identification and subtyping of 
Fusarium.16,17,21,22 Accurate species identification of Fusarium spp. is important not only to 
promote our understanding of the spectrum of Fusaria pathogenic to the eye, but such 
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information may also yield important prognostic and therapeutic information for the patient 
and clinician in the future. 
Many different genes have provided the basis for the development of molecular 
based identification techniques, including ribosomal RNA (rRNA), translation elongation 
factor (EF-1!), the second largest subunit of RNA polymerase II (RPB2), and domains 
D1/D2 of the nuclear large subunit (LSU).17,21,23,24 Many fungal genotyping studies have 
relied on the rRNA gene complex for rapid species identification.13,14,25-30 This gene family 
comprises four ribosomal rRNA genes: the 26-28S, 18S, 5.8S and 5S genes, which are 
arranged as head to tail tandem repeats separated by the spacer regions, the internal 
transcribed spacer region (ITS) and the intergenic spacer region (IGS) (Figure 1). Although 
rRNA genes are highly conserved, the ITS regions are typically variable and rich in 
informative sites, hence their usefulness for phylogenetic classification.28,29 Although the 
ability of the ITS region to differentiate medically important species within Fusarium 
species complexes has been reported, no study has fully examined the utility of the allelic 
variability within this single locus to differentiate Fusarium spp. isolates from ocular 
sources alone.  In this study, we employ sequence data analysis of the ITS region as well 
as traditional morphological classification to elucidate the phylogenetic diversity of 
Fusarium spp. strains isolated from ocular tissue and contact lens paraphernalia of 
patients diagnosed with Fusarium keratitis in south Florida.    
 
 
METHODS 
 
Fungal isolates:  
A total of 58 fungal isolates from ocular sources of 52 patients were selected from 
the archived samples at the Bascom Palmer Eye Institute’s ocular microbiology laboratory 
(BPEI-OML) - University of Miami (Miami, FL).  The isolates were obtained from patients 
with culture-proven infectious keratitis, which had been examined at BPEI between April 
2000 and May 2007. The isolates were obtained from 41 corneas, 4 aqueous humor 
samples, 1 vitreous sample, 8 contact lenses and 4 contact lens cases (Table 1). The 
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archived isolates were retrieved from their lyophilized state at BPEI-OML and grown in 
pure culture supplemented with peptone-yeast-glucose (PYG) (Remel, Lenexa, KS) media 
or on Sabouraud dextrose agar.  Species identification was provided for 30 isolates at 
BPEI-OML (Miami, FL). In addition 30 of 58 isolates (due to funding restraints) were sent 
to the reference fungal laboratory, Texas Fungus Testing Laboratory (TFTL, University of 
Texas Health and Science Center (San Antonio, TX)) for species identification following 
molecular characterization.  The 30 isolates were selected following genotypic 
characterization to include all of the F. non-solani isolates as well as 17 randomly selected 
F. solani isolates.  Traditional identification of filamentous molds were performed using a 
combination of macroscopic (texture, color, growth rate, media) and microscopic 
techniques (conidia formation).31 
 
DNA extraction:  
The fungi were grown on Sabouraud dextrose agar plates for 7 days, transferred to 
15 ml centrifuge tubes containing 2 ml of PBS solution, and centrifuged at 3000 rpm for 10 
minutes.  The supernatant was removed and DNA was isolated using a modified UNSET 
procedure.32 Briefly, one ml of UNSET lysis buffer (urea 8 M, sodium dodecyl sulfate 
(SDS) 2%, NaCl 0.15 M, EDTA 0.001 M, Tris pH 7.5 0.1 M) was added to the fungal 
pellets and vortexed for 5 sec.  An equal volume of phenol:chloroform:isoamyl alcohol 
(25:24:1) was added to the solution, along with 0.3g of acid-washed glass beads, and the 
tubes vortexed for 5 min. The samples were centrifuged for 5 min at 13000 rpm and the 
aqueous phase was transferred to a new 1.5 ml Eppendorf tube.  The phenol-
chloroform:isoamyl alcohol extraction procedure was repeated until satisfactory removal of 
the protein interface was achieved.  The aqueous phase was precipitated with a 1/10th 
volume of 3 M sodium acetate and 1 volume of isopropanol addition. The tubes were 
centrifuged for 10 min at 13200 rpm at 40C and the supernatant was decanted. The DNA 
pellets were rinsed with1 ml of 70% ethanol and the tubes centrifuged again for 10 min at 
13200 rpm.  The supernatant was then decanted and residual ethanol was removed. The 
remaining ethanol was evaporated using a vacuum centrifuge at 45oC for 2 min. The 
resulting DNA pellet was re-suspended in 30"l of distilled water and the genomic DNA was 
stored at -20 oC. 
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The quality and concentration of the genomic DNA was assessed through 
spectrophotometric determination of the UV absorbance 260/280 nm ratio (Eppendorf Bio 
Photometer, Westbury, NY) and by gel electrophoresis of the sample with a 1KB molecular 
weight ladder (Invitrogen, Carlsbad, CA).  
 
DNA amplification:  
PCR reactions were performed with 200 ng of genomic DNA. The primers F18S (5’-
GCGGAGGGATCATTACCGAGTT-3’) and F28S (5’-CAGCGGGTATTCCTACCTGATC-3’) 
(Invitrogen, Carlsbad, CA) were designed to specifically target Fusarium spp.  F18S primer 
is located at the end of the 18S ribosomal DNA at position 520-540 of F. solani reference 
strain Fs-27 (GeneBank # EF432243)), whereas F28S is located at the beginning of the 
28S rRNA at position 41-62 of the sequence EF432243.  The described set of primers 
amplified the internal transcribed spacer region comprising ITS1, ITS2 and the 5.8S rRNA. 
The PCR reaction used the Accuprime Taq DNA Polymerase System: a 25 "l Polymerase 
Chain Reaction (PCR) mixture contained 1 "l (200 ng) of DNA template, 2.5 "l of buffer II 
solution (containing the dNTP’s and MgCl2 ), 1 "l of each 10 "m primer (F18S and F28S), 
1 "l of Taq DNA polymerase (Invitrogen, Carlsbad, 78CA) and 18.5"l of distilled water. 
PCR reactions were performed in a thermocycler (Bio-Rad iCycler, Hercules, CA), and 
employed 1 cycle at 95 oC for 3 min, followed by 45 cycles with a denaturation step at 95 
oC for 30 sec, an annealing step at 55 oC for 30 sec, and an extension step at 68 oC for 2 
min.  A negative control was included in all experiments. The detection of amplified 
products was performed by electrophoresis of an aliquot of 5 "l of each amplicon in a 1% 
agarose gel with ethidium bromide 0.02% in 1X tris-acetate-EDTA (TAE) buffer. The DNA 
bands were visualized under UV illumination (Bio-Rad Universal Hood II, Hercules, CA). A 
1 KB molecular weight ladder was included in each run (Invitrogen, Carsbad, CA). PCR 
products were purified using Geneclean spin kit (MPBiomedicals, Solon, OH) according to 
manufacturer’s instructions. 
 
DNA sequencing:  
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Direct sequencing of PCR products was performed by Genewiz, Inc (South 
Plainfield, NJ) with Applied Biosystems BigDye version 3.1. The reactions were run on 
Applied Biosystem’s 3730x1 DNA Analyzer. The PCR amplification primers, F18S and 
F28S, were used as the sequencing primers and the PCR products were sequenced on 
both strands in duplicate or triplicate to assure sequence fidelity.  
 
Phylogenetic analysis:  
Two hundred and sixty three sequences, which varied in size from 509 to 535 base 
pairs (bp), were aligned using MegaAlign - (DNAStar, WI) and by manual adjustment to 
form the consensus sequences for the 58 isolates. The percent identity of the aligned 
sequences was also determined with the program Megalign. The phylogenetic trees were 
computed with MEGA 4.0 (Molecular Evolutionary Genetic Analysis software, ver. 4.0; 
http://www.megasoftware.net)33 using maximum-parsimony analysis. The sequence of the 
ITS region from the pathogenic fungus, Lecanicillium lecanii was used as the outgroup 
group (GeneBank accession number DQ007051). For the purposes of comparison and in 
order to have a more complete representation of the spectrum of ophthalmologically 
important fusaria, the ITS region from 11 isolates deposited into GeneBank 
(http://www.ncbi.nlm.nih.gov/genbank) by O’Donnell et al.21 were included in the data set 
(USDA identification codes: NRRL 43529, 43536, 43445, 43468, 43489, 43375, 25483, 
43656, 13604, 43504, 43726). The neighbor-joining tree utilized the Kimura two-parameter 
distance algorithm, produced in MEGA 4. Bootstrap values for the maximum parsimony 
tree (MPT) were obtained from a consensus tree based on 100 randomly generated data 
sets with jumbled sequence addition. All positions containing gaps were eliminated from 
the dataset. 
 
Nucleotide sequence accession numbers:   
All DNA sequence data reported in this paper have been deposited in GenBank 
under accession numbers: EU721670 to EU721727. 
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RESULTS 
The 58 isolates analyzed in this study are shown in Table 1. Morphological 
classification at the  BPEI-OML identified 28 isolates only to the genus level (Fusarium 
spp.), 19 isolates as F. oxysporum, and 11 isolates as F. solani.  Thirty of the isolates were 
sent to the TFTL for morphological confirmation. Of these, 17 isolates were classified as 
belonging to the F. solani species complex (FSSC), 9 to the F. oxysporum species 
complex (FOSC) and 4 to the F. incarnatum-equiseti species complex (FIESC).    The 
sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) 
for the different identification techniques are shown in Table 2.  Because of the limited 
sample size in this study, the organisms were classified as either F. solani species 
complex (FSSC) or F. non-solani species complex (FNSSC) for these calculations.  
FNSSC is defined as all isolates not classified genotypically as F. solani. 
Sequence analysis of the 58 ITS consensus sequences (509 to 535 bp) identified 
15 unique haplotypes, 8 of which comprised multiple isolates (Table 1).  Nucleotide 
differences among the isolates ranged from 0% to 18% within and between species (Table 
3). Figure 2 shows a maximum parsimony tree (MPT) rooted by the outgroup Lecanicillium 
lecanii, a close relative to the Fusarium genus. The MPT (Fig. 2) shows supported 
resolution of the isolates into their particular species complex as indicated by bootstrap 
values ranging from 74 to 99% for the four species complexes identified in this study. Four 
major species complexes were represented in the ocular infections (Table 4): F. solani 
(FSSC) (75%), F. oxysporum (FOSC) (16%), F. incarnatum-equiseti (FIESC) (5%), F. 
dimerum (FDSC) (2%) and one isolate (2%) that did not fit any species complex.. The 
phylogenetic relationships between isolates within the FSSC were unresolved due to the 
lack of informative sites with this group (Table 3 and Fig 2).   
The FSSC grouping was well supported by a terminal bootstrap value of 99%. The 
distance-based phylogenetic reconstruction also supported this grouping based on the 
small evolutionary distances within the FSSC. Isolates within this group had differences 
ranging from 0-4% and evolutionary distance less than 3.8% (Table 3). EU721706, 
EU721716 and EU721726, which share a unique sequence and were morphologically 
classified as F. incarnatum-equiseti, differed from members of the FOSC by less than 5%. 
This grouping was also supported by a terminal bootstrap value of 99%. The isolate 
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EU721689, morphologically classified as F. incarnatum-equiseti by TFTL and as Fusarium 
roseum by AOML, differs from members of the other species complexes by 14 to 18%.  It 
is most similar to the Fusarium chlamydosporum species complex (FCSC) (14% sequence 
variability) and least similar to FOSC (18% sequence variability), suggesting it represents a 
new complex group. A database search of GeneBank identified the isolate as 
Colletotrichum sp, Nectria sp or Fusarium sp. 
 
 
DISCUSSION 
This study examined the genetic diversity of Fusarium spp. isolates derived from 
patients diagnosed with infectious keratitis at the Bascom Palmer Eye Institute in Miami, 
FL.  Toward this end, we studied the feasibility of using the ITS region for the detection 
and identification of Fusarium spp. from ocular sources to the species level.  In addition, 
we compared this molecular classification technique to classification based on examination 
of morphologic characteristics.   
In this study Fusarium spp. isolates causing ocular infections fell within 4 main 
species complexes: FSSC, FOSC, FIESC, and FDSC, with a similar relative frequency 
previously reported.21,22 57% of the isolates were represented by the 3 most common 
haplotypes (a, c, k).  O’Donnell et al.21,22 genotyped 191 isolates using multilocus 
sequence typing (MLST) of the nuclear large rRNA subunit (LSU), translation elongation 
factor (EF-1!), and two contiguous regions of the RNA polymerase II second largest 
subunit (RPB2). This study used isolates from ocular and environmental sources obtained 
from the Center of Disease Control (CDC) investigation into the contact lens associated 
Fusarium keratitis outbreak. Their phylogenetic study nested the isolates causing ocular 
infection into 5 different species complexes: FSSC (62%), FOSC (29%), GFSC (6%) 
(Gibberella fujikuroi species complex), FIESC (4%), and FDSC (1.0%).  No GFSC or 
FCSC isolates were identified in the present study, likely as a result of either small sample 
size, or differences in sampling region compared to other studies.  Of note, only one case 
of FCSC-associated keratitis has been reported in the literature.34 
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The isolate EU721689 exhibited significant sequence variability (14-18%) when 
compared to other isolates in this study (Table 3). This isolate may be representative of 
another Fusarium species complex still not defined or may represent an organism from 
another genus.  However, both microbiology laboratories morphologically classified this 
isolate as Fusarium spp.  The clinical outcome was typical of an infection caused by F. 
non-solani isolate, with a good final visual acuity and without the need for surgical 
intervention.  A database search of GeneBank identified the isolate as Colletotrichum spp, 
Nectria spp or Fusarium spp.   
Taxonomic identification of Fusarium sp has its limitations in a diagnostic setting. In 
this study, genus level taxonomic identification was 100% accurate at both BPEI-OML and 
TFTL compared to genotypic classification.  Species classification of the 30 selected 
isolates performed by TFTL was accurate and in concordance 100% of the time with the 
genotypic data.  In contrast, a remarkable discrepancy was observed in species 
assignment performed at BPEI-OML, where only 30 of the 58 isolates were assigned a 
species designation, which proved to have an accuracy of 50% when compared to the 
genotypic identification, due to a low sensitivity for the F. solani isolates. Because non-
reference clinical laboratories are not typically equipped to identify fungal organisms to the 
species level, this result is not altogether unexpected. Laboratory species designation 
based solely on microscopic and morphological traits can be prone to misinterpretations 
because morphological characteristics of certain fungal elements are not always clear.   In 
fact, strains belonging to the same species may display different morphological 
characteristics at different growth stages.14  Additionally, micro and macroscopic 
characteristics may be influenced by media, age of culture and identification schema.31 
Therefore, the success of this traditional method of identification relies on the taxonomic 
experience of the personnel that undertake such tests.  These difficulties discourage more 
than 90% of microbiology laboratories from identifying fungi species altogether.   
Genus and species-specific identification of fungi using microbiologic techniques is 
also time intensive.  Such techniques generally require about 3 and 7 days, respectively, 
even when undertaken at a fungal reference laboratory.  In contrast, the use of PCR and 
sequence analysis is capable of identification of Fusarium isolates to the genus and 
species level in less than 24 hours.  In this study, sequencing was undertaken by another 
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institution which increased the total time required for species identification to 3 days. 
Although this study was performed from cultured isolates, our preliminary and unpublished 
data shows PCR is capable in detecting Fusarium with the DNA contained in 1 spore, even 
with the addition of background human DNA.  Therefore, we believe it is possible to 
amplify DNA directly from a fraction of the clinical sample in cases of Fusarium keratitis, 
and it is unlikely that subculture will be necessary in future molecular-based diagnostic 
tests. 
 The present study highlights two attractive features of the ITS region: a) the 
region aligned well across the spectrum of isolates represented in ocular infections; and b) 
the nucleotide variation provided strong bootstrap support to allow for the placement of 
98% of the isolates within one of six monophyletic species complexes (Table 3).   
Additionally, the ITS region lies within a multicopy gene, which is important in a clinical 
diagnostic setting, particularly in the field of ophthalmology, where sample size is very 
limited.  The multicopy nature of the gene would theoretically result in increased assay 
sensitivity when applied within the context of a PCR-based diagnostic test.11  
While the allelic variation within the ITS region allowed reliable placement of the 
vast majority of isolates within one of the six species complex groups, the ability of this 
region to clearly differentiate distinct clades within each of these six species complexes is 
limited, particularly when compared to MLST.21,22 Although this MLST technique described 
by O’Donnell et al.21,22 is capable of more detailed classification, this level of identification 
may not be required in a clinical setting.  When developing a cost effective and efficient 
molecular based analysis in a clinical setting, it is important to determine the level of 
identification which remains clinically relevant.  Moreover, to what level do differences exist 
among the different species with regards to pathogenicity and antifungal susceptibility 
profiles that can potentially influence management decisions of the treating physician?   
The Fusarium genus is largely resistant, both in vivo and in vitro, to the current 
available antifungal agents.22,24,35  However, previous studies have demonstrated 
antifungal MICs that are typically higher and more variable for Fusarium than for other 
pathogenic filamentous fungi36, thus it may be of interest to establish susceptibility profiles 
among the different species as determined by molecular classification techniques.  
Repeatedly, broth microdilution studies based on NCCLS guidelines have demonstrated F. 
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solani to carry higher levels of resistance to available antifungal agents (in particular 
amphotericin B and voriconazole) than F. non-solani species.24,36,37 Similarly, O’Donnell et 
al.22 studied the in vitro activity of 10 antifungals against 20 isolates representing 18 
species that span the breadth of the FSSC phylogeny and found broad resistance across 
this complex without species-specific differences in susceptibility patterns.   
In a recent report of 52 patients with Fusarium keratitis, differences in clinical 
characteristics among the different species complexes concluded that infections due to 
organisms within the FSSC, in contrast to non-FSSC organisms, were associated with 
worse final best corrected visual acuity, a longer resolution time and higher penetrating 
keratoplasty rate (Oechsler RA, et al. IOVS 2008;49: ARVO E-Abstract 2495).   These 
findings suggest higher pathogenicity among the FSSC isolates in the setting of infectious 
keratitis.   
Patient 9 was the only patient from which isolates with different haplotypes were 
recovered.  The first isolate was from a corneal scraping of the right eye in April 2004, and 
the second isolate was from the patient’s right contact lens, also cultured in April 2004.  
This suggests that Fusarium isolates obtained from contact lens or other associated 
paraphernalia do not necessarily correlate with the organism causing the ocular infection.  
Interestingly, one case has been reported in the literature in which two different Fusarium 
genotypes were isolated from the same eye of a patient with infectious keratitis.7   Although 
difficult, it may be clinically important to acknowledge a dual infection, as antifungal 
susceptibility patterns are known to be widely variable among the different Fusarium 
isolates,22,24,35 and the choice of antifungal medication may be influenced by such 
information. 
 Although in vitro and clinical correlation studies have demonstrated differences in 
susceptibility and pathogenicity profiles among the Fusarium species complexes, studies 
utilizing an animal model of infectious keratitis are necessary to compare the pathogenic 
potentials as well as the in vivo susceptibility profiles of each species complex.  
Nonetheless, these existing reports encourage proper identification to the species complex 
level, which may aid the clinician to provide important prognostic and therapeutic 
information that may, in fact, influence clinical decisions.    
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In summary, the ITS region provides a sufficient genetic scaffolding to detect and 
reliably differentiate Fusarium spp. isolates that cause ocular infections into one of six 
species complex groupings, a level of identification which appears to hold clinical 
relevance. In theory, the ITS region is an ideal candidate on which to base the 
development of a rapid molecular test for the diagnosis of infectious etiologies. When 
compared with MLSTs, the ITS region offers a less complex, more efficient, and more cost 
effective means of differentiating ocular Fusarium isolates to a level that will influence 
clinical decision making.   
Such DNA-based diagnostic tests show significant promise in allowing precise and 
rapid diagnosis of fungal ocular infections, and their design and implementation will 
certainly hasten the initiation of appropriate antimicrobial therapy and guide clinical 
management decisions, hopefully decreasing ocular morbidity associated with fungal 
ocular infections. 
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Table 1. Summary of Fusarium spp isolates examined. 
Patient 
number Source 
 
 
Year 
BPEI-OML 
classification 
Reference 
lab 
classification Genotype 
 
 
Haplotype 
GenBank 
accession 
number 
1 Cornea 2005 F solani FSSC FSSC a EU721672* 
2 CL case 2006 F sp FSSC FSSC a EU721721 
3 Cornea 2006 F oxysporum FSSC FSSC b EU721688* 
4 
Contact Lens 
(CL) 2003 F sp 
- 
FSSC a EU721708 
5 Cornea 2006 F sp FSSC FSSC a EU721704 
6 CL 2006 F sp FSSC FSSC b EU721683 
7 Cornea 2004 F sp - FSSC b EU721701 
8 Cornea 2006 F sp - FSSC b EU721671 
9† Cornea 2004 F solani - FSSC a EU721677 
9† CL 2004 F solani - FSSC i EU721674* 
10 Cornea 2006 F solani - FSSC d EU721693* 
11 Cornea 2004 F oxysporum - FSSC c EU721724* 
12† Cornea 2006 F sp - FSSC c EU721692 
12† Cornea 2006 F sp FSSC FSSC c EU721690 
13 Cornea 2007 F solani - FSSC e EU721680* 
14 Cornea 2007 F oxysporum - FSSC c EU721686 
15 Cornea 2005 F sp FSSC FSSC f EU721702* 
16 Cornea 2004 F sp - FSSC c EU721722 
17 Cornea 2005 F oxysporum - FSSC c EU721714 
18 Vitreous 2005 F sp - FSSC c EU721678 
19† Cornea 2006 F sp FSSC FSSC c EU721673 
19† CL 2006 F sp - FSSC c EU721711 
20 Cornea 2005 F oxysporum - FSSC c EU721696 
21 Cornea 2006 F oxysporum FSSC FSSC c EU721717 
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22 CL 2006 F sp FSSC FSSC c EU721681 
23 Cornea 2006 F sp - FSSC c EU721703 
24 Cornea 2007 F solani - FSSC g EU721679* 
25 Cornea 2006 F sp FSSC FSSC g EU721705 
26 
Anterior Chamber 
(AC) 2006 F solani 
- 
FSSC h EU721691* 
27 Cornea 2004 F solani - FSSC g EU721695 
28 Cornea 2000 F oxysporum FSSC FSSC g EU721687 
29 Cornea 2007 F oxysporum - FSSC g EU721684 
30 Cornea 2007 F oxysporum - FSSC g EU721699 
31 Cornea 2005 F oxysporum - FSSC g EU721698 
32 Cornea 2007 F oxysporum FSSC FSSC g EU721697 
33 Cornea 2006 F sp - FSSC g EU721675 
34 Cornea 2006 F oxysporum - FSSC g EU721725 
35 Cornea 2006 F oxysporum - FSSC g EU721719 
36 Cornea 2005 F solani FSSC FSSC g EU721676 
37 Cornea 2007 F solani FSSC FSSC j EU721670* 
38 Cornea 2004 F solani - FSSC i EU721694 
39† AC 2004 F oxysporum FSSC FSSC i EU721715 
39† AC 2006 F oxysporum FSSC FSSC i EU721700 
40 Cornea 2006 F sp - FSSC j EU721727 
41† CL case 2006 F oxysporum FOSC FOSC k EU721709* 
41† CL 2006 F oxysporum FOSC FOSC k EU721718 
42 Cornea 2006 F sp FOSC FOSC k EU721712 
43† CL case 2005 F sp FOSC FOSC k EU721710 
43† CL 2006 F sp FOSC FOSC k EU721713 
44 Cornea 2006 F sp FOSC FOSC k EU721685 
45 Cornea 2006 F oxysporum FOSC FOSC k EU721682 
46 CL 2006 F sp FOSC FOSC l EU721720* 
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47 CL 2006 F sp FOSC FOSC k EU721723 
48 CL 2006 F oxysporum FIESC FIESC m EU721716* 
49 CL 2006 F sp FIESC FIESC m EU721726 
50 Cornea 2006 F sp FIESC FIESC m EU721706 
51 Cornea 2004 F sp - FDSC n EU721707* 
52 Cornea 2007 F sp FIESC No fit o EU721689* 
Notes: a)patients with 2 isolates from the same eye were marked with ”†”; b) the accession numbers with a mark (*) were used to 
build the maximum parsimony tree (Figure 1). 
FSSC= Fusarium solani species complex;  
FOSC= Fusarium oxysporum species complex;  
FDSC= Fusarium dimerum species complex;  
FIESC= Fusarium incarnatum-equiseti species complex; 
 
 
 
 
Table 2.  Correlation of morphologic-based vs. genotype-based classification. 
 Genotypic 
identification 
(N=58) 
BPEI’s microbiology 
laboratory  (N=30) 
Fungal reference 
laboratory (N=30) 
Species 
complex 
FSSC/FNSSC FSSC FNSSC FSSC/FNSSC 
Sensitivity 100% 42% 100% 100% 
Specificity 100% 100% 42% 100% 
PPV 100% 100% 21% 100% 
NPV 100% 21% 100% 100% 
Accuracy 100% 50% 50% 100% 
FSSC= Fusarium solani species complex;  
FNSSC= Fusarium non-solani species complex (group gathering all other species complexes).  
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Table 3. Identity among the 15 different haplotypes and outgroup. 
 
 
Table 4. Genetic identification breakdown of the 58 isolates and comparison to the 
reference genotypic classification for medically important Fusarium spp. 
Species complex Present study O’Donnell et al (2007) 21 
FSSC 44 (75%) 62%  
FOSC 9 (16%) 29% 
FIESC 3 (5%) 2% 
FDSC 1 (2%) 1% 
FCSC - - 
GFSC - 6% 
Unidentified 1 (2%) - 
FSSC= Fusarium solani species complex;  
FOSC= Fusarium oxysporum species complex;  
FDSC= Fusarium dimerum species complex;  
FIESC= Fusarium incarnatum-equiseti species complex; 
FCSC= Fusarium chlamydosporum species complex;  
GFSC= Gibberella fujikuroi species complex. 
 
Figure 1. Ribosomal RNA (rRNA) genes, transcribed spacer regions (ITS 1 and 2) and 
primer locations. 
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Figure 2.  Maximum Parsimony Tree (MPT) analysis created with sequence data from the 
ITS 1 and 2 regions and rooted with the outgroup sequence of Lecanicillium lecanii. 
 
Notes: a) the letters in parenthesis following the accession numbers correspond to the haplotypes listed in Table 1; b) 
The NRRL isolate sequences included for comparison were reported by O’Donnell et al. (O’Donnell); c) The marked 
isolate (*) did not fit into any of the species complex groupings. 
FSSC= Fusarium solani species complex;  
FOSC= Fusarium oxysporum species complex;  
FDSC= Fusarium dimerum species complex;  
FIESC= Fusarium incarnatum-equiseti species complex; 
FCSC= Fusarium chlamydosporum species complex;  
GFSC= Gibberella fujikuroi species complex. 
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Abstract 
 
Purpose:  To determine differences in the clinical characteristics and antifungal 
susceptibility patterns among molecularly characterized ocular Fusarium sp isolates. 
 
Methods:  58 Fusarium isolates obtained from 52 eyes of 52 patients were retrieved from 
the Bascom Palmer Eye Institute’s (BPEI) ocular microbiology laboratory and grown in 
pure culture.  These isolates were characterized based on DNA sequence analysis of the 
ITS1/2 and ribosomal DNA (rDNA) regions.  Antifungal susceptibilities were determined for 
each isolate using broth microdilution methods and the corresponding medical records 
were reviewed to determine clinical outcomes. 
 
Results: Fusarium (F.) solani isolates had significantly higher voriconazole MIC90 values 
than F. non-solani organisms (16 and 4ug/ml, respectively).  F. solani isolates also 
exhibited a significantly longer time to cure (65 vs 40.5 days), a worse follow up BCVA 
(20/118 vs 20/36), and increased need for urgent surgical management (7 vs 0 penetrating 
keratoplasties) when compared to F. non-solani isolates. 
 
Conclusions: This is the first report to examine the correlation between ocular genotyped 
Fusarium species and clinical outcomes. It supports the overall worse prognosis for F. 
solani versus F. non-solani isolates, including higher voriconazole resistance by the 
former. The clinical implementation of molecular-based diagnostics and antifungal efficacy 
testing, may yield important prognostic and therapeutic information that could improve the 
management of fungal ocular infections. 
 
 
Key words: keratitis, Fusarium sp, genotyping, antifungal, clinical outcomes. 
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Introduction 
 
 Following the recent global outbreak of contact lens associated Fusarium keratitis 
(2005-2006) there has been a renewed interest and significant focus of research 
establishing epidemiology, classification, diagnosis and treatment standards.  It is now 
clear that the incidence of Fusarium keratitis has increased dramatically over the past 4 
decades, accounting for up to 50% of all microbial keratitis cases in tropical climates. 1-9  
This increasing incidence is multi-factorial and is believed to be due to increased 
awareness and changes in risk factor profiles throughout the global population, including 
an increase in the use of topical steroids and antibacterial agents, as well as an increase in 
surgical procedures, contact lens use, ocular trauma, chronic ocular surface diseases, and 
immune compromised patients 6, 10-13. 
 Among the Fusarium species that are pathogenic to the eye, F. solani is the most 
common, followed by F. oxysporum, F. dimerum, F. incaratum-equiseti, and Gibberella 
fujikuroi. 14, 15 Microbiologic techniques have long served as the diagnostic gold standard in 
the setting of fungal keratitis. Such techniques are capable of reliably differentiating among 
the different molds and yeasts causing keratitis.  Although highly accurate at genus 
identification, (Fusarium, Aspergillus, Candida, ect.) morphologic classification of Fusarium 
isolates to the species level using microbiologic techniques (F. solani, F. oxysporum, etc) 
is problematic and inconsistent due to the large degree of morphologic variability 
demonstrated at different growth stages.15, 16 In light of the increasing incidence of 
Fusarium keratitis, this inconsistency in morphologic identification has generated 
significant interest in finding a more consistent and reliable basis for organism 
classification. Recent reports have demonstrated genotypic identification systems as a 
more accurate and reproducible means of properly identifying ocular Fusarium pathogens 
14, 17 and a clear consensus has emerged 18-21 that DNA sequence-based methods will be 
essential for rapid species identification of the Fusarium genus in clinical laboratories22. 
 The question remains: is it clinically important to accurately differentiate between 
the different Fusarium species causing keratitis?  Recent reports suggest that filamentous 
fungi harbor unique species-specific in vitro susceptibility profiles to the existing and 
emerging antifungal agents 23-25. Within the Fusarium genus and among isolates 
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pathogenic to the eye, however, these species-specific antifungal susceptibility profiles 
have not been firmly established 26, 27. Furthermore, although the etiology and 
epidemiology of Fusarium keratitis has been well studied 3-5, 28, 29, very little has been 
revealed about the differences in clinical characteristics and outcomes associated with 
infections due to different Fusarium species.  
 In this study, we investigate and compare the in vitro susceptibility profiles and 
provide the first report of the clinical characteristics and outcomes among ocular 
pathogenic Fusarium isolates classified by genotypic analysis. Such information is useful 
from a prognostic, diagnostic and therapeutic viewpoint to determine the level of pathogen 
identification that has the potential to directly influence practice patterns and patient 
outcomes. 
 
 
Methods 
 
Isolates:  
 Fifty-eight Fusarium sp isolates, representing 52 patients, were retrospectively 
selected from the Bascom Palmer microbiology isolate library based on the morphologic 
species classification to include approximately 20 isolates of each: F. solani, F. oxysporum 
and F. species without further designation. We included consecutive isolates from May 
2005 to June 2007.  In addition, this group of isolates was supplemented with samples 
dating back to April 2000 to achieve the desired equal distribution from each morphological 
designation.  The source distribution of the isolates was cornea (41), aqueous humor (4), 
vitreous (1), contact lens (8), and contact lens case (4).  A recent paper from the authors of 
this study 15, explains in detail the genotyping procedures, conforming to the most recent 
Fusarium species complexes classification system14, 21.  
The quality control (QC) reference strains Candida albicans from American Type Culture 
Collection (ATCC) 90028, Candida parapsilosis ATCC 22019, Candida krusei ATCC 6258 
and Aspergillus flavus ATCC 204304 were included as control isolates for the Clinical and 
Laboratory Standards Institute (CLSI) (Formerly NCCLS) testing method. 
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Antifungal Agents:   
 The methodology as described in the CLSI document M38-A reference was 
followed for broth dilution antifungal susceptibility testing of filamentous fungi.  Additive 
drug dilutions were prepared to yield twice the final strength required for the test.  Stock 
solutions of amphotericin B (AMB) and natamycin (NAT) at their final concentrations were 
frozen at -80 C until needed.  The agents evaluated in this study have well-established 
microdilution MIC ranges for these QC strains (M38-A).  Thirty isolates were also sent to 
the University of Texas fungal testing laboratory for voriconazole (VOR) susceptibility 
testing and identity confirmation (following CLSI M38-A methodology). 
 
Medical records review:   
 Following Institutional Review Board (IRB) approval, the medical records from 50 of 
the 52 affected patients were available for review. All patients included in the chart review 
had positive corneal culture results for Fusarium sp growth or positive culture from contact 
lens paraphernalia plus clinical and confocal microscopy appearance of filamentous fungal 
corneal infection.  
 The follow up BCVA of patients who underwent penetrating keratoplasty (PK), was 
the last BCVA measured prior to surgery. For this group of patients, the time to cure was 
assigned as an estimate, which was the longest time to cure among clinically treated 
patients. 
   The follow up BCVA of the patients treated with topical or oral antimicrobial agents, 
was the VA measured when the patient was considered cured (inactive corneal scar with 
intact epithelium). 
 Snellen visual acuities were converted to logMAR by the formula logMAR acuity = 
minus log (numerator Snellen/denominator Snellen) for the purpose of data analysis.  
Vision levels classified as count fingers, hand motion, light perception, and no light 
perception were assigned Snellen acuities of 1/200, .5/200, 20/20,000, and 20/200,000.  
The corresponding logMAR VAs were 2.3, 2.6, 3.0, 4.0 respectively, similar to a previously 
published scale 30.  
 Statistical analyses were performed using SPSS software version 15.0 (SPSS Inc, 
Chicago, Illinois, USA). Tests of significance were two-tailed with p #0.05 for all tests. 
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Univariate comparisons between F. solani and F. non-solani were performed using the 
two-sided Student t-test for continuous variables. Non-parametric tests (Mann-Whitney 
Test) were used for analyzing the data which does not follow normal distribution. Chi-
square or Fisher’s exact test was performed for categorical variables. Analysis of Variance 
(ANOVA) was performed for multiple comparisons. 
 
 
Results 
 
Microbiological and Molecular Identification 
 Identification of the organisms as belonging to the Fusarium genus took a mean of 
3.6 (±2.9) days, with a range of 2 to 12 days, whereas identification to the species level 
using microbiological techniques required a mean of 8 (±3.7) days. 
 Molecular identification took up to 24 hours to identify the isolates to the species 
level. Based on genotype, the 58 isolates were classified into one of five groups:  F. solani 
species complex (FSSC) (75%), F. oxysporum species complex (FOSC) (16%), F. 
incarnatum-equiseti species complex (FIESC) (5%), F. dimerum species complex (FDSC) 
(2%), and Fusarium species not otherwise identified (2%).  Sequence analysis showed 15 
distinct sequences among the 58 isolates.  For the purposes of data analysis, and due to 
isolate characteristics homogeneity, the isolates were divided into 2 groups: F. solani and 
F. non-solani, which includes all species other than F. solani. 
 
Clinical Characteristics and Epidemiology 
 The 58 samples were isolated from 52 eyes of 52 patients.  The clinical 
characteristics are shown in table 1. 
 The follow up time in this study had a mean of 7.3 (±6) months, ranging from 15 
days to 24 months. The time from the onset of symptoms until the first evaluation at BPEI 
ranged from 1 to 33 days, with a mean of 6.6 (±7.1) days. No patients had additional 
pathology at baseline that accounted for decreased visual acuity at any time during the 
management. 
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 The infiltrates involved the central 6mm of the cornea in 36 of 50 cases, with no 
difference observed between F. solani (71%) and F. non-solani isolates (75%).  Compared 
to peripheral infiltrates, central infiltrates were associated with a statistically significant 
worse initial BCVA (20/235 and 20/33, respectively, p<0.001, t-test) and final BCVA 
(20/142 and 20/28, respectively, p=0.001, t-test) when compared to peripheral infiltrates. 
 
Risk factors 
 Risk factors for infectious keratitis were found in 49 patients (Figure 1). Among the 
38 patients with F. solani infection, 24 were CL wearers (63%) and among the 12 patients 
with F. non-solani infection, 9 were CL wearers (75%).  The frequency of trauma history 
between F. solani and F. non-solani infections was similar (20%) in both groups. Three 
patients had history of previous topical steroid use (2 in the F. solani and 1 in the F. non-
solani group). 
  
Management 
 Complete information of the treatment protocols was present in the records of 48 
patients. Both topical and systemic antimicrobial agents were used for treatment of these 
infections. Topical natamycin 5% (Natacyn®, Alcon Labs, Fort Worth, TX) was used in 41 
cases, and was used as monotherapy in 26 cases and in combination with other 
antimicrobial agents in 15 cases. Topical voriconazole 1% (compounded from Vfend®, 
Pfizer Inc, New York, NY) was prescribed in 7 cases, oral fluconazole 100mg (generic 
fluconazole, Cipla Pharmaceuticals, Mumbai, India) BID in 6 cases, topical amphotericin B 
0.15% (compounded from generic amphotericin B, X-Gen Pharmaceuticals Inc, Big Flats, 
NY) in 4 cases, moxifloxacin 0.5% (Vigamox®, Alcon Labs, Fort Worth, TX) in 3 cases, 
combination of fortified cefazolin 5% (compounded from generic cefazolin, Abraxis 
BioScience, Los Angeles, CA)  with tobramycin 1.4% (compounded from Ak-Tob® 0.3%, 
Akorn, Lake Forest, IL + generic tobramycin, Hospira Pharmaceuticals, Lake Forest, IL) in 
3 cases each and oral valacyclovir 500mg  (Valtrex®, GlaxoSmithKline, London, UK) 
3x/day in 1 case. 
 Therapeutic penetrating keratoplasty (PK) was necessary in 7 cases, all of which 
were caused by F. solani isolates.  The time from diagnosis to PK ranged from 4 to 57 
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days, with a mean of 28 (±22) days. The indications for PK were perforation in 4 cases and 
severe infiltrates non-responsive to clinical therapy in 3 cases. Four of the therapeutic 
grafts failed (three due to rejection and one to stromal melting) and repeat PK was 
successful in 2 cases. 
 
Outcomes 
 Treatment delay (Figure 2) and time to cure (Figure 3) had a significant correlation 
with the follow up BCVA of F. solani versus F. non-solani isolates. 
 Among the 26 patients that received natamycin as monotherapy, 22 (85%) ended 
with BCVA $ 20/40, and the other 4 patients (15%) had a follow up BCVA between 20/60 
and 20/80 (Table 2). 
 Natamycin was used as combined therapy in 15 cases, 11 used natamycin with 
azoles. Eight of these patients (73%) underwent PK or had final BCVA < 20/400.  The 
other three patients (27%) had a good final outcome, with BCVA $ 20/40. 
 Among the 9 patients with a follow up BCVA <20/200, risk factors were identified in 
8 cases (6 CL wearers, 2 used previous topical steroids, 2 immunosupressed patients) and 
PK was performed in 6 cases. The initial BCVA in this group was LogMAR 1.25 (20/355) 
and follow up BCVA 1.66 (20/915).  
  
Antifungal Susceptibility Testing  
 Minimum inhibitory concentrations for 50 and 90% of the isolates (MIC50 and MIC90), 
medians, and MIC ranges for F. solani and F. non-solani isolates are listed in table 3.  
 In general, the isolates were equally susceptible to natamycin and amphotericin B. 
F.solani organisms had significantly higher voriconazole MIC values than F. non-solani 
organisms. 
 
 
Discussion 
 
 A wide spectrum of Fusarium is known to be pathogenic in the human eye. Our 
improved understanding of this spectrum begs the questions we set forth to address in this 
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study, namely to determine clinical characteristics and antifungal susceptibilities within the 
Fusarium genus. Currently, the literature describing these relationships is sparse.  Defining 
these inherent qualities is critical to determining the clinical significance of accurate and 
rapid species identification.  
 
Clinical Characteristics and Outcomes 
 In this study, F. solani isolates were associated with significantly longer treatment 
course (p=0.035, Mann-Whitney test), worse follow up BCVA (p=0.01, t-test), and higher 
necessity for PK compared to F. non-solani isolates. These observations suggest 
increased pathogenicity and differences between in vitro and in vivo antifungal 
susceptibility among F. solani isolates compared to other species within the genus.  
 Interestingly, F. solani isolates were associated with poorer outcomes compared to 
other species of Fusarium, despite slight differences between in vitro susceptibilities for the 
most commonly available and utilized topical antifungal agents (natamycin and 
amphotericin B).  This observation suggests that other factors may be responsible for this 
discordance between in vitro and in vivo antifungal activities, like inter-species differences 
in pathogenicity. 
 Systemically, F. solani organisms are significantly more pathogenic and incur a 
higher risk of mortality compared to F. non-solani isolates 31. The suggestion of enhanced 
pathogenicity among F. solani isolates (compared to other Fusarium species) observed in 
our study, as well as other non-ocular studies, may be explained by species-specific 
differences in virulence strategies, including organism adherence to the ocular surface 32, 
invasion of the organism into the corneal stroma 33, or alteration of host and pathogen 
defense mechanisms 34.   
   
Antifungal susceptibility 
 The increasing use of DNA-based identification schemes to accurately and rapidly 
identify fungal organisms to the species level has brought to light the importance of 
defining specific antifungal susceptibility profiles.  This is particularly important for the 
Fusarium genus, for which minimum inhibitory concentrations (MIC’s) are higher and more 
variable than for other molds (e.g. Aspergillus sp) 23, 26, 27. 
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 The results of the in vitro susceptibility tests from the isolates in this study (Table 2, 
3) demonstrated high levels of in vitro resistance among Fusarium sp to available 
antifungal agents, particularly when compared to published susceptibility profiles of other 
filamentous fungi, including Aspergillus sp and Paecilomyces sp 26, 35-38. Across the 
Fusarium genus, amphotericin B had the lowest MIC values. Finally, different patterns of 
susceptibility were noted among the different Fusarium species. Specifically, this study 
demonstrates significantly higher MIC values (p<0.001, Mann-Whitney test) for 
voriconazole among F. solani isolates compared to F. non-solani isolates.   
 By the present date, six studies have explored in vitro antifungal susceptibility 
patterns among genetically characterized Fusarium isolates 26, 27, 37-40.  These studies 
consistently demonstrate variable MICs and high levels of resistance across the spectrum 
of antifungal agents.  
 Repeatedly, F. solani isolates have been reported to exhibit greater resistance to 
antifungal agents than F. non-solani in studies using both morphologic identification 23, 25, 
41-45 and molecular characterization 37-39.  Among the studies utilizing reliable molecular 
identification techniques to characterize the isolates 37-39, F. solani isolates demonstrated 
higher levels of resistance to voriconazole, posaconazole, and pentamidine when 
compared to other members of the Fusarium genus.  
  
Management  
 In the present study, 11 patients received a combined therapy of natamycin and 
azoles. A statistically significant amount of patients in this group experienced a worse 
outcome (follow up BCVA < 20/40 and loss of $2 lines of BCVA) when compared to the 
other groups (p<0.001 and 0.032, Chi-square test, respectively). Alternatively, the cases 
with combination therapy may have had more severe disease which was not reflected by 
the visual acuity. Of note, it has been demonstrated that combination treatment may 
produce antagonistic interactions in vitro, particularly when natamycin is used in 
combination with azoles 46. 
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Limitations of the study 
 The lower prevalence of F. non-solani when compared with F. solani infections, did 
not allow for selection of an even distribution of Fusarium species to be genotyped.  In 
future studies, an equal distribution and larger number of isolates from all species would 
provide more power for further inter-species comparisons. Furthermore, due to the 
inherent limitations in a retrospective study, the clinical data was incomplete in some 
cases, specifically risk factor assessment and follow-up information. 
 
  
Conclusions 
 
 This study demonstrates important differences in antifungal susceptibility profiles 
and clinical characteristics among Fusarium isolates causing keratitis, and suggests inter-
species differences in virulence mechanisms yet to be explored.  Future studies comparing 
in vitro and in vivo antifungal activity of the available antifungal agents alone and in 
combination will allow us to accurately assess drug interactions and optimize specific 
treatment strategies.  Furthermore, this study suggests that accurate species identification, 
especially if performed with rapid PCR techniques, may yield important prognostic and 
therapeutic information that can influence management decisions and improve patient 
outcomes in the setting of Fusarium keratitis.   
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Figure 1. Risk factors among Fusarium sp keratitis patients*. 
 
*There were 6 patients that had more than 1 risk factor. 
 
Figure 2. Correlation of treatment delay and follow up BCVA for F. solani vs F. non-solani 
isolates. 
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Figure 3. Time to cure versus follow up BCVA in patients with Fusarium sp keratitis  
 
 
 
 
 
Table 1. Clinical characteristics of Fusarium sp keratitis 
 Fusarium sp 
total (N=50) 
F. solani 
(N=38) 
F. non-solani 
(N=12) 
p-value 
Male 22 (44%) 17 (45%) 5 (42%) Gender 
Female 28 (56%) 21 (55%) 7 (58%) 
1.00*  
Age (mean(SD)) 39 (19) 39 (20) 40 (18) 0.97**  
CL wear 33 (66%) 24 (63%) 9 (75%) 0.51*  
Trauma 9 (18%) 7 (18%) 2 (17%) 1.00*  
Infiltrate’s location    
Central 6mm 36 (72%) 27 (71%) 9 (75%) 
Peripheral 14 (28%) 11 (29%) 3 (25%) 
1.00* 
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Smear (+) results:      
Cornea 14/34 (41%) 11/29 (38%) 3/5 (60%) 0.63* 
CL case 1/12 (8%) 1/5 (20%) 0/7 (0%) 0.42*  
Anterior chamber 0/3 (0%) 0/3 (0%)  0 N/A 
Vitreous 0/1 (0%) 0/1 (0%) 0 N/A 
Total 15/50 (30%) 12/38 (32%) 3/12 (25%) 1.00*  
Time to (+) culture†  
(days) 
3.6 (2.9) 
(Range:2-12) 
3.5 (3.1) 
(range:2-12) 
3.8 (2.1) 
(range:2-11) 
0.8** 
Treatment delay 
(days) 
9.7 (7)  
(range: 0-35) 
10.3 (7.6) 
(range: 0-35) 
7.2 (4.3) 
(range:1-12) 
0.22** 
Time to cure 
(days) 
60 
(range: 10-
100) 
65 
(range:10-
100) 
40.5 
(range:10-92) 
0.035*** 
Initial BCVA 
LogMAR (Snellen) 
0.83 (20/135) 
(range:20/20-
LP) 
0.89(20/155) 
(range: 20/20-
LP) 
0.65 (20/89) 
(range: 20/25-
HM) 
0.38** 
Follow up BCVA 
LogMAR (Snellen) 
0.65 (20/89) 
(range:20/20-
LP) 
0.77 (20/118) 
(range: 20/20-
LP) 
0.25(20/36) 
(range:20/20-
20/100) 
0.01** 
Penetrating 
Keratoplasty 
7 (14%) 7 (18%) 0 (0%) 0.17*  
Follow up 
BCVA<20/200 
9 (19%) 9 (25%) 0 (0%) 0.09* 
Treatment delay= time from the onset of symptoms to the initiation of antifungal agents. 
Time to cure= duration of treatment necessary to eliminate evidence of clinically active infection. 
N/A= not applicable 
* Fisher’s exact test 
** t-test 
*** Mann-Whitney test 
†
 Genus level (Fusarium sp) 
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Table 2. Treatment regimen versus visual outcomes.  
 
 Nata Only  
(N=26) 
Nata+Azoles 
(N=11) 
Nata+Others 
(N=4) 
Others 
(N=7) 
P-value 
Mean Initial 
BCVA 
0.66(0.73) 
20/91 
1.27(0.99) 
20/372 
0.54(0.38) 
20/69 
0.92(0.99) 
20/166 
0.20* 
Mean Follow 
up BCVA 
0.24(0.46) 
20/35 
1.74(1.24) 
20/1099 
0.11(0.08) 
20/26 
0.73(1.12) 
20/107 
<0.001* 
Mean BCVA 
improvement 
0.43(0.67) -0.47†(1.23) 0.43(0.31) 0.32(0.42) 0.03* 
Initial BCVA  
Better than 
or equal to 
20/40 
11 (42.3%) 1 (9.1%) 2 (50%) 2 (28.6%) 0.22** 
Follow up 
BCVA Better 
than or equal 
to 20/40 
22 (88%) 3 (27.3%) 4 (100%) 4 (66.7%) 0.001** 
BCVA 
improve 2 or 
more lines 
14 (56%) 2 (18.2%) 4 (100%) 3 (50%) 0.032** 
*Analysis of Variance (ANOVA) was performed. 
** Chi-Square Test 
†Mean follow up BCVA was worse than mean initial BCVA. 
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Table 3.  Voriconazole, Natamycin and Amphotericin B MIC50’s, MIC90’s and medians 
(ug/ml). 
 Voriconazole  Amphotericin B  Natamycin  
 MIC50 
MIC90 
(range) 
Media
n 
p-
value 
MIC50 
MIC90 
(range) 
Media
n 
p-
value 
MIC50 
MIC90 
(range) 
Media
n 
p-
value 
F. solani 
 (n=44) 
16 
16 
(4- $16) 
n=15 
16 <0.001
* 
2 
2  
(1-$16) 
n=43 
2 0.07* 4.8 
4.8  
(2.4-
9.6) 
n=44 
4.8 0.37* 
F. non-
solani 
(n=14) 
4 
4  
(2-$16) 
n=12 
4  2 
2  
(1-2) 
n=14 
2  2.4 
4.8  
(2.4-
4.8) 
n=14 
3.6  
MIC50 and MIC90 values at 48 hours. 
*Mann-Whitney Test 
 
 
 
 
 
 
 
 
 
 
!
!
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Abstract 
 
Purpose:  To describe clinical characteristics and determine correlations between clinical 
outcomes and antifungal susceptibility among molecularly characterized ocular Fusarium 
sp isolates in Brazil. 
Methods:  41 Fusarium isolates obtained from 41 eyes of 41 patients were retrieved from 
the Sao Paulo Federal University’s Ophthalmic microbiology laboratory and grown in pure 
culture. These isolates were genotyped and antifungal susceptibilities were determined for 
each isolate using a broth microdilution method. The corresponding medical records were 
reviewed to determine clinical outcomes. 
Results: The 41 isolates were genotypically classified into:  F. solani species complex 
(FSSC) 36 isolates (88%), F. oxysporum species complex (FOSC) 2 isolates (5%), F. 
dimerum species complex (FDSC) 1 isolate (2%) and 2 isolates did not group into any of 
the species complexes. Final best corrected visual acuity (BCVA) varied from 20/20 to light 
perception and was in average 20/800 (LogMAR 1.6). Trauma history was the most 
frequent risk factor, being present in 21 patients (51%). Therapeutic penetrating 
keratoplasty (PK) was necessary in 22 patients (54%). Amphotericin B had the lowest 
MIC90 value (2ug/ml), and voriconazole the highest (16ug/ml). There was an association 
between a higher natamycin MIC and therapeutic penetrating keratoplasty necessity 
(Mann-Whitney test, p<0.005). 
Conclusions: Trauma was the main risk factor, and therapeutic PK’s were necessary in 
54% of the patients. AMB had the lowest MIC90(2ug/ml) among the 3 tested antifungals. 
There was an association between higher natamycin MIC levels and corneal perforation, 
emphasizing the need for antifungal susceptibility testing and the tailoring of antifungal 
strategies. 
 
Key words: keratitis, Fusarium sp, genotyping, antifungal, clinical outcome 
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Introduction 
 
 Brazil, as other countries having an important territorial part in the tropical zone, has 
a significant amount of fungal keratitis cases, varying from 11 to 56% of all positive 
cultures.1,2 In countries like India and China, fungi can be the etiology of up to 36 and 62% 
of all keratitis cases, respectively.3,4 Among the fungi causing keratitis, Fusarium sp is the 
most prevalent. Studies show 45 to 67% of fungal keratitis in Brazil, being caused by this 
microorganism.1,2,5-7 Among the Fusarium species that are pathogenic to the eye, F. solani 
is the most common (up to 91% of isolates)7, followed by other species as F. oxysporum 
and F. dimerum.8,9  
 Treatment of keratomycosis is still largely empirical, without a consensus on the role 
of susceptibility testing in choosing the most appropriate therapy. Ocular microbiology 
laboratories do not routinely perform antifungal susceptibility testing, as it is time 
demanding, laborious and challenging especially for molds. However, in vitro resistance of 
Fusarium spp. isolates against many of the available antifungal agents has been 
demonstrated to be common mainly among F. solani. Studies have already shown that 
there is a correlation between antibiotic susceptibilities and clinical oucomes in bacterial 
keratitis.10-12 Some studies are starting to show that a relationship between antifungal 
susceptibility and clinical outcomes might also exist in fungal keratitis cases.13-15 Current 
methods for testing antifungal susceptibility have significantly improved. Fusarium spp. 
MIC determination has demonstrated to be clinically relevant and is a valuable information 
for choosing the best topical antifungal therapy. 
 There is a lack of epidemiological and clinical information on fungal ulcers in Brazil. 
Also, information on antifungal susceptibilities and correlation to clinical outcomes is 
limited, and such information will be very usefull to improve treatment strategies for 
Fusarium sp, the main pathogen of fungal keratitis cases in Brazil and many other 
countries. In the present study 41 isolates from 41 patients presenting Fusarium sp 
keratitis were identified by genotyping, tested for their antifungal susceptibility to 
natamycin, amphotericin B and voriconazole and correlated with their clinical outcomes. 
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Methods 
 
Isolates:  
 Fourty one Fusarium spp. isolates, representing 41 patients, were retrospectively 
selected from the Ocular Microbiology Laboratory, Federal University of Sao Paulo, based 
on the medical records’ availability. We included isolates from 1997 to 2010. The source of 
all isolates was corneal scrapings from patients with keratitis.  The reference strains 
Candida albicans ATCC 90028, Candida parapsilosis ATCC 22019 and Candida krusei 
ATCC 6258 were included as quality control (QC) for the Clinical and Laboratory 
Standards Institute (CLSI) antifungal testing method. The morphologic species-specific 
identification of all strains was performed at the Federal University of Sao Paulo’s 
Mycology Laboratory. 
 
Medical records review:   
 Following Institutional Ethics Committee (Comitê de Ética em Pesquisa da 
Universidade Federal de São Paulo) approval (registration number 1066/08), the medical 
records from the 41 affected patients were available for review. All patients included in the 
chart review had positive corneal culture results for Fusarium sp. 
 The follow up BCVA of the patients treated with topical or oral antimicrobial agents, 
was the visual acuity (VA) measured when the patient was considered cured (inactive 
corneal scar with intact epithelium). No patients had additional pathology at baseline that 
accounted for decreased visual acuity at any time during the management. 
 The final best corrected visual acuity (BCVA) of patients who underwent therapeutic 
penetrating keratoplasty (PK), was the last BCVA measured prior to surgery. For this 
group of patients, the time to cure was assigned as an estimate, which was the longest 
time to cure among clinically treated patients. 
 Snellen visual acuities were converted to the logarithm of the minimum angle of 
resolution (logMAR) for the purpose of data analysis.  Vision levels classified as count 
fingers (CF), hand motion (HM) and light perception (LP) were assigned Snellen acuities of 
1/200, .5/200 and 20/20,000.  The corresponding logMAR VAs were 2.3, 2.6 and 3.0 
respectively, similar to a previously published scale.16 
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Antifungal susceptibility tests:   
 The methodology as described in the CLSI document M38-A217 was followed for 
broth dilution antifungal susceptibility testing of filamentous fungi.  Additive drug dilutions 
were prepared to yield twice the final strength required for the test.  Stock solutions of 
amphotericin B (AMB), voriconazole (VOR) and natamycin (NAT) at their final 
concentrations were frozen at -80oC until needed.  The agents evaluated in this study have 
well-established microdilution minimum inhibitory concentration (MIC) ranges for these QC 
strains.  
 
Isolates and DNA extraction  
Fourty two Fusarium spp. isolates, collected from 41 patients seen at Department of 
Ophthalmology, Federal University of São Paulo, were retrospectively selected from the 
Ocular and Molecular Microbiology Laboratory culture collection, based on the medical 
records availability. All isolates were recovered from corneal scraping cultures of patients 
with infectious keratitis clinically diagnosed.  Frozen isolates on skim milk were cultured 
twice on Sabouraud agar. Total fungal DNA was extracted from fresh cultured isolates 
after boiling for 15 minutes using the PrepMan ultra sample preparation reagent (Applied 
Biosystems).   
 
 
Amplification and Sequencing of ITS region 
The internal transcribed spacer region comprising ITS1, ITS2, and 5.8S rRNA was 
amplified in a 25-"L PCR mixture containing 10 µL GoTaq Green PCR Master Mix 
Promega (3.0 mM MgCl, 200µM dNTPs, buffer and 1 U Taq DNA polymerase), 0.4 µM of 
each following primers, F18S (5’-GCGGAGGGATCATTACCGAGTT-3’) and F28S (5’-
CAGCGGGTATTCCTACCTGATC-3’), 1 "L DNA template and DEPC water.  Amplification 
was performed using the Master Cycler gradient termocycler (Eppendorf) with the following 
conditions: 1 cycle at 95°C for 3 minutes, followed by 45 cycles with a denaturation step at 
95°C for 30 seconds, an annealing step at 55°C for 30 seconds, and an extension step at 
68°C for 2 minutes. The amplification was carried out in the presence of negative and 
positive controls. Amplified products separated in a 1% agarose gel were purified using 
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QIAquick purification kit (Qiagen). PCR products were sequenced on both strands using 
the Big Dye Terminator chemistry on the 3000 ABI Genetic Analyzer (Applied Biosystems). 
Sequences obtained were edited using SeqMan (DNAStar, WI) and searched for similarity 
in GenBank using the BLAST (blastn algorithm) program with automatically adjusted 
parameters.  
 
Phylogenetic Analysis 
Before alignment sequences were scanned for quality using Phred base calling program. 
The upstream and downstream regions just after the primer annealing regions were 
manually trimmed (SeqMan, DNASTAR, Madison, WI). Thirty nine edited sequences 
ranging from 502 to 566 bp exported as FASTA file were aligned using Muscle multiple 
sequence alignment algorithm (implemented by MEGA 5.1 Molecular Evolutionary 
Genetics Analysis).18  Assignment of haplotypes was accomplished using DnaSP v5. For 
comparison purposes in the phylogenetic tree, sequences of ITS region representing a 
recent Fusarium species complexes classification system (O’Donnel) were included. The 
ITS sequence from Lecanicillium lecanii was employed as an outgroup (DQ007051). 
Selection of the substitution model that best fit the data as well as estimation of model 
parameters such as base pair frequencies, substitution rates, transition and transversion 
ratio, proportion of invariant sites and gamma shape parameter were computed using 
jModeltest.19 Bayesian phylogenetic tree implementing the general time reversible (GTR) 
model with a proportion of invariable sites and gamma-distributed rate variation across 
sites was constructed using MrBayes v3.1.2.20 Posterior probabilities of the tree were 
estimated by running two simultaneous and independent Metropolis-coupled Monte-Carlo 
Markov chains with 3 heated and 1 cold chain for 5 million generations. Chains were 
sampled every 100th cycle.  Consensus tree was summarized after discarding the first 25% 
generations as burn-in. Tree was visualized and edited using Mesquite v2.75.21  
 
Nucleotide Sequence Accession Numbers 
The ITS nucleotide sequences reported in this work have been deposited in GenBank 
under accession numbers JX270136, JX270138 to JX270143, JX270148 to JX270153, 
JX270157 to JX270173 and JX270175 to JX270183.  
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Statistical analyses 
Performed using Stata software version 11.0 (College Station, Texas, USA). Tests of 
significance were two-tailed with p #0.05. Fisher’s exact test was performed for categorical 
variables. Non-parametric test (Mann-Whitney Test) was used for analyzing the data which 
does not follow normal distribution (Antifungals’ MICs).  
 
 
Results 
 
Identification 
 Morphologic identification of the organism as belonging to the Fusarium genus took 
a mean of 5.8 days, with a range of 2 to 14 days. The identification to the species level, 
took 4 more days in average, after genus classification. Morphology-based identification, 
classified the 41 isolates as follows: 35 F. solani, 4 F. oxysporum and 2 F. dimerum. 
 Based on genotype, the 41 isolates were classified into one of three groups:  F. 
solani species complex (FSSC) 36 isolates (88%), F. oxysporum species complex (FOSC) 
2 isolates (5%), F. dimerum species complex (FDSC) 1 isolate (2%) and 2 isolates did not 
group in any species complex. The relation among the genotyped isolates is shown in the 
consensus tree (Figure 1). In the major species complex found, FSSC, 16 distinct 
haplotypes were identified. Haplotype D was the most frequent among FSSC (13 out 34 
sequences; 38.2%). The posterior probability that supports the whole FSSC clade was 
63%. An internal subcluster including the haplotypes c, k, p and q clustered together with 
posterior probability support of 91%. FDSC and FOSC groups, represented each one by a 
single haplotype, were supported by a posterior probability of 98% and 100% respectively.  
 
 
Clinical Characteristics and Epidemiology 
 The 41 samples were isolated from 41 eyes of 41 patients.  The clinical 
characteristics are shown in tables 1and 2. The follow up time in this study was in average 
9.3 months, ranging from 1 to 24 months. Time to diagnosis, defined as the interval from 
symptoms onset until a specific diagnosis was made, ranged from 3 to 90 days, with a 
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mean of 19±12 days. Risk factors for infectious keratitis were found in 26 patients. Trauma 
history was the most frequent risk factor, being present in 21 patients (51%).  
    
Management 
 Complete information of the treatment protocols was present in the records of 37 
patients. Patients which had a positive culture and/or microscopy for a mold, were started 
on a topical antifungal, wheter 5% natamycin or 0.15% amphotericin B hourly. For ulcers 
larger than 6mm in diameter or if no improvement with topical antifungal use after 5 days 
was seen, a systemic antifungal was added (Ketoconazole 200mg or Fluconazole 200mg 
BID). 
Topical amphotericin B 0.15% (compounded from Fungizon®, Bristol-Myers Squibb, New 
York, NY, USA) was used in 24 cases, being as monotherapy in 7 cases and in 
combination with other antimicrobial agents in 15 cases. Topical natamycin 5% 
(Pimaricina®, Ophthalmos, Sao Paulo, Brazil) was used in 14 cases, as monotherapy in 
only 1 case. Oral fluconazole 150mg (generic fluconazole, Medley Pharmaceuticals, 
Campinas, SP, Brazil) or Ketoconazole 200mg (generic ketoconazole, Medley 
Pharmaceuticals, Campinas, SP, Brazil) BID were used in 29 cases. 
 Therapeutic penetrating keratoplasty (PK) was necessary in 22 patients (54%). The 
indications for PK were perforation in 19 cases and severe infiltrates non-responsive to 
clinical therapy in 3 cases. Seven of the therapeutic grafts failed (four due to reinfection, 
two to rejection and one to stromal melting) and repeat PK was successful in only one 
case, which initially had failed due to rejection. 
 
Antifungal Susceptibility Testing  
 Antifungal susceptibilities were tested for 38 isolates. Minimum inhibitory 
concentrations for 90% of the isolates (MIC90), medians, and MIC ranges for the Fusarium 
isolates are listed in table 3.  
 Amphotericin B had the lowest MIC values, and voriconazole the highest. Most of 
the isolates were equally susceptible to natamycin and amphotericin B.  
 There was a strong association between a higher natamycin MIC and PK necessity 
(Table 4). 
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Discussion 
 
 Fungal keratitis is a very prevalent disease in developing countries. These cases 
tend to have a poorer outcome when compared to keratitis caused by other pathogenic 
organisms. Fusarium sp is the leading pathogen in fungal keratitis in most of the studies 
worldwide, specially in tropical regions.3-7 Information on epidemiology, antifungal 
susceptibilities and correlation to clinical outcomes is lacking and such information is 
useful from a prognostic, diagnostic and therapeutic viewpoint. 
 In the present study, the main genotypically identified species-complex was FSSC 
(F. solani), in 88% of patients. Other study performed in the same institution 8 years ago, 
found a similar frequency (91%).7 Morphology-based identification showed 85% of the 
isolates belonging to the F. solani species. One isolate which was morphologically 
classified as F. dimerum, when identified afterwards by genotyping, showed to be actually 
FSSC. And 2 isolates morphologically identified as F. oxysporum, were genotypically 
classified as belonging to the Fusarium genus but did not group in any species complex. 
Overall, the accuracy of the morphologic identification, which was performed in the present 
study by a mycology laboratory, was 97,6%. In a previous study by the same author, a 
discrepancy of up to 50% between morphology and genotype-based identification was 
found, when species-specific morphologic identification was performed by a general 
microbiology laboratory.9 In this previous study, based on the morphologic identification, a 
shift occurred towards mistakenly identifying F. oxysporum instead of F. solani. 
 Most of the affected patients were male (83%) and in a productive age (mean 46 
years), which agrees with various other studies on fungal keratitis.6,22,23 This is probably 
due to the fact that males, specially in working age, are more involved in outdoor activities, 
with a greater exposure to foreign bodies and traumas. 
 Comparing outcomes among the different species of Fusarium in this study, the 
only significant difference was a higher therapeutic PK necessity among the F. solani, 
when compared to the F. oxysporum and F. dimerum isolates (Fischer’s exact test, 
p=0.05). Another study performed by the same authors in South Florida, also 
demonstrated F. solani isolates showing a higher therapeutic PK rate when comparing to 
other Fusarium species.24 It has been demonstrated that F. solani has the capacity to form 
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more biofilm than other species complexes.25 The ability to form biofilm makes the isolate 
more resistant to the antifungal agents compared to their planktonic counterpart (without 
biofilm). F. solani biofilms have demonstrated reduced susceptibility mainly for AMB and it 
could in part explain the worse clinical outcomes for F. solani compared to other Fusarium 
species.  
 Of note, the majority of studies published on this subject and used for comparison, 
describe outcomes for fungal keratitis in general, not specifically Fusarium sp keratitis 
cases. The only study found in the literature which shows specifically Fusarium keratitis 
outcomes, was performed by Alfonso et al.26  
 In the present study, final visual outcomes were poor, with a mean final BCVA of 
1.60 LogMAR (20/800), ranging from 20/25 to LP. Final BCVA was "20/40 in only 11% and 
#20/200 in 64% of the patients. Another study performed in Brazil also showed poor final 
BCVA, >20/40 in 28% and <20/200 in 63% of patients.5 We found much better final BCVA 
results in studies performed in other countries. In a study from China, with early surgical 
intervention, final BCVA was "20/40 in 47% and #20/200 in only 4% of patients4. Two 
studies in the United States (US) also showed data on visual acuities: in North Florida 56% 
of patients had "20/40, and in South Florida, 65% had "20/50 and 18% <20/100.26,27 
 Therapeutic grafts were necessary in this study for 22 patients (54%). Other study 
in Brazil had a 38% therapeutic PK rate.5 This is a high incidence, when compared to 
studies carried out in developed countries, which showed incidences of PK between 21 
and 25% of the cases.27-30 On the other hand, in developing countries, there is still a high 
incidence of PKs necessary to treat fungal keratitis cases, being necessary in 40 to 47% in 
India13,31 and performed in 88% of severe cases in a study in China.4 
 Time to diagnosis, defined as the interval from symptoms onset until a specific 
diagnosis was made, was in average 19 days, ranging from 3 to 90 days. This was a long 
interval, considering each day of delay decreases the chance of a good visual outcome. As 
being a reference center, many cases only reach a specific diagnosis and treatment after 
being treated by one or more general physicians or ophthalmologists. In one study 
performed in the US, a time to diagnosis of 9 days in average was found.26 Another study 
in the US found a mean time to presentation of 9 days.27 In China, a study showed a mean 
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time to presentation of 27 days.4 A study from India found that patients with a time to 
presentation of more than 10 days had statistically significant higher surgical intervention, 
mostly due to corneal perforation.31 
 Trauma was found to be the main risk factor, in 51% of the patients. Of these, 62% 
were from organic sources. Other studies in Brazil and abroad corroborate this finding, 
being well known that trauma and foreign bodies are an important source of fungal ocular 
infections.4-6,27,30 Steroid use was found to be present in 15% of the patients. In other 
studies, it varied from 7 to 26%.4,26,27  
 A low CL wear incidence (5%) among the studied patients has been found. Studies 
in developed countries as US, show higher rates of CL wear among the risk factors, 
varying from 40 to 47%, and up to 52% during the CL-related outbreak in 2005-06.26,27,30 A 
study in China, with mostly rural patients, had none of 654 fungal keratitis cases with a CL 
wear history.4 This demonstrates a worldwide variation in CL-related fungal keratitis 
prevalence, and in Brazil, as in China and other developing countries, CL wear is a less 
frequent risk factor for fungal keratitis, being trauma still the most important risk factor. 
 A long time to cure was also found, with an average of 110 days. Typically, fungal 
ulcers take a longer time to heal than bacterial ulcers. The long time to diagnosis found in 
this study may be one of the main factors implicated in increasing the severity of the 
disease and enlongating the time to cure. This outcome was found to be shorter in studies 
performed in US, varying from 53 to 67 days.26-28 
 In this study, the results of the in vitro susceptibility tests (Tables 2 and 3) 
demonstrated mostly high MIC levels among Fusarium sp to available antifungal agents, 
particularly when compared to published susceptibility profiles of other fungi, as 
Aspergillus sp and Candida sp.32,33  
Antifungal sensitivity was not significantly different among species of Fusarium, 
probably due to the small amount of Fusarium non-solani isolates. AMB was the tested 
drug with the lowest MIC levels against Fusarium isolates (MIC90 = 2ug/ml), as seen in 
other susceptibility studies in US, 2ug/ml,34,35 Italy, 2ug/ml,36 and China 2ug/ml4 and 
4ug/ml.37 NAT had a MIC90 of 8ug/ml in our study, which varied in one dilution in other 
studies: 4 ug/ml22,35 for isolates from US and India, 8 and 16ug/ml for 2 other studies in 
India.14,15 In the present study, VOR had a MIC90 of 16ug/ml. Other studies testing VOR for 
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Fusarium sp, found a MIC90 as low as 4ug/ml in US,
34 8 ug/ml in Italy36 and 16 ug/ml in 
China.37 This shows the high MICs for antifungals necessary to treat Fusarium sp in 
general, especially for VOR. Other fungi, as Aspergillus and Candida sp, are more 
susceptible to azoles than Fusarium sp, particularly to VOR.32 
In the present study, NAT had a MIC90 of 8ug/ml and AMB of 2ug/ml for the tested 
isolates. Due to the inherent toxicity of AMB eye drops, the commonly used topical 
concentration for this drug is 0.15% (1.5mg/ml), while it is 5% (50mg/ml) for NAT. This 
difference of about 30 times between NAT and AMB concentrations, and only 2 dilutions 
difference in MIC90 between them showed in this study, made NAT eyedrops to be used as 
the first line antifungal agent for Fusarium sp keratitis in our institution. 
Interestingly, an association between higher NAT MIC levels and need of 
therapeutic PK due to corneal perforation was found. A recent study from a fungal corneal 
ulcer clinical trial in India, also showed that higher NAT and VOR MICs were associated 
with an increased chance of corneal perforation.14  
Previous studies have demonstrated lower MICs are correlated with better 
outcomes as reepithelialization occurs earlier for those cases.14,15 Isolates presenting 
higher MICs are more difficult to treat and take more time to respond to the therapy. Poor 
penetration of antifungal agents in the corneal stroma is also a limiting factor for clearing 
quickly the infection.38 Taken together, higher MIC levels and antifungals’ typical poor 
tissue penetration, hamper achievement of pharmacodynamic targets and therapeutic 
levels of these drugs, contributing to worse clinical outcomes.  
In Brazil, NAT and AMB are the mainstay of treatment for fungal corneal ulcers. 
Thus, it is reasonable to think that a association between higher NAT MICs and higher 
incidence of corneal perforation may exist. This data corroborates the fact that antifungal 
susceptibility testing may be important to guide the therapy of Fusarium sp keratitis cases.  
 Because of inherent limitations in a retrospective study, the clinical data was 
incomplete in some cases, specifically risk factors and some follow-up information. A small 
sample size of Fusarium non-solani isolates was available, due to the high F. solani 
prevalence in Brazil. In future studies, a larger number of isolates from all species may 
provide more power for Fusarium inter-species comparisons. 
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Conclusions 
 
In the present study, we discussed epidemiological data of Fusarium sp keratitis 
genotyped isolates from a reference center in Brazil. Trauma was the main risk factor 
(51%), and therapeutic PK’s were necessary in 54% of the patients. A poor follow up 
BCVA has been shown (average of 20/800), also a long time to diagnosis (19±12 days) 
and time to cure (110±72 days). We also performed antifungal susceptibility tests and 
correlated it with clinical outcomes. AMB had the lowest MIC90(2ug/ml) among the 3 
antifungal agents tested. There was an association between higher natamycin MIC levels 
and corneal perforation. Our study shows that Fusarium sp keratitis have a poor outcome, 
especially in developing countries, and suggests that more resistant strains have a higher 
risk of corneal perforation, emphasizing the need for antifungal susceptibility testing and 
the tailoring of antifungal strategies. 
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Figure 1. Consensus Bayesian phylogenetic tree of the ITS 1 and ITS 2 regions  
summarized after discarding as burn-in the first 25% generations of the Metropolis-coupled 
Markov chain Monte Carlo analysis. Numbers in the branches indicates the posterior 
probabilities estimative. Letter in parenthesis correspond to the haplotype. Only one 
sequence of each haplotype was represented in the tree. The parenthesis marked (*) 
represents isolates that did not group into any species complex. FSSC, Fusarium solani 
species complex; FOSC, Fusarium oxysporum species complex; FDSC Fusarium dimerum 
species complex.    
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Table 1. Clinical characteristics of the keratitis cases. 
Patient Fusarium 
species 
Age 
(years) 
Gender Risk factors Treatment 
delay (days) 
Time to 
cure (days) 
1 sol 54 M - 10 180 
2 sol 17 M - 90 102 
3 sol 56 M Trauma 30 70 
4 sol 52 M Trauma 28 60 
5 sol 36 M Trauma 19 270 
6 sol 37 M Trauma 10 90 
7 sol  46 M Trauma 48 110 
8 sol  44 M Conjunctivitis 8 150 
9 sol 52 F - 18 - 
10 sol 85 M Trauma 30 180 
11 sol 41 F - 18 240 
12 sol 31 F Trauma 10 180 
13 sol 20 M Conjunctivitis 16 90 
14 sol 49 M Trauma 7 150 
15 sol 32 M - 12 45 
16 sol 42 M Trauma 10 60 
17 sol 39 M Trauma 30 60 
18 sol 59 F Trauma 40 180 
19 sol 47 M Trauma 15 60 
20 sol 20 M Trauma 30 60 
21 sol 53 M Trauma - 112 
22 sol 40 F Conjunctivitis 25 240 
23 sol 33 M Trauma - - 
24 sol 60 M Trauma 26 180 
25 sol 54 M Trauma 15 180 
26 sol 52 M - 45 90 
27 sol 36 M Trauma 15 60 
28 sol 35 M - 12 90 
29 sol 66 M Trauma 4 60 
30 sol 48 M Trauma 30 90 
31 sol 46 M - 3 36 
32 sol 40 M - 18 60 
33 sol 47 F - 20 30 
34 sol 76 F - 20 - 
35 sol 49 M - 21 30 
36 sol 73 M - 17 - 
37 oxy 49 M - - 105 
38 oxy 30 M CL 7 30 
39 dim 28 M CL 4 15 
40 spp 57 M Surgery 21 90 
41 spp 41 M Conjunctivitis 7 240 
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Totals/ 
Means 
36 F. sol 
2 F. oxy 
1 F. dim 
2 F. spp 
45±14.7 34 M 
7 F 
20 Trauma 
4 Conjunctivitis 
2 CL 
1 Surgery 
19±12.4 107±71.5 
Legend: sol= F. solani; oxy= F. oxysporum; dim= F. dimerum; M=Male; F=Female 
 
 
 
Table 2. Clinical characteristics of the keratitis cases (continuation). 
Patient Initial 
BCVA 
Final 
BCVA 
Ulcer 
location 
Prior 
steroid 
PK Treatment 
given 
MIC 
NAT/VOR/AMB 
1 2.3 2.0 C No PK N,K 4/8/4 
2 2.3 1.6 - - - - 8/8/1 
3 2.3 2.0 C No - N,K,F 0.125/8/0.5 
4 0.8 0.2 C Y - A 4/8/0.5 
5 2.3 2.3 C No PK N,A,F 4/4/2 
6 0.1 0.1 C Y - N,K 4/16/1 
7 2.6 2.3 - No PK N,K 8/8/4 
8 2.0 0.5 C No - N,K 4/8/4 
9 1.0 0.4 - - - A - 
10 2.6 2.6 C No PK K 4/4/0.5 
11 3.0 2.6 C - PK A,K 4/16/2 
12 2.6 2.0 C No PK N,K,A 8/8/2 
13 2.3 0.4 C No - A 1/16/1 
14 2.6 2.6 C No PK A,K 4/8/2 
15 0.4 0.4 C No - N,K 4/2/4 
16 2.0 2.0 C No PK N,A,K 4/2/2 
17 0.4 0.5 C No - N,K 0.03/8/0.5 
18 2.3 2.6 C No PK A,K 4/8/2 
19 0.7 0.1 C No - N,K 0.125/8/0.25 
20 0.7 0.7 P No - N,K 8/4/4 
21 1.6 1.6 - - - - 4/16/2 
22 3.0 2.3 C No PK A 8/8/4 
23 2.3 - - No - - 4/8/1 
24 2.6 2.0 C No PK K 4/4/1 
25 2.6 2.3 C No PK A,K 0.25/4/0.5 
26 2.3 2.3 C No PK A 8/8/2 
27 0.7 0.5 C Y - A,K 4/8/1 
28 2.3 2.0 C No PK A,K 8/4/2 
29 0.9 0.4 P Y - A,K - 
30 2.3 - C No PK A,F,K - 
31 2.6 2.3 C Y PK A,K 8/8/1 
32 2.3 2.3 P - PK N,K 8/16/0.5 
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33 2.0 2.3 C No - A 4/8/0.5 
34 2.6 2.6 - - PK A,K 8/2/0.5 
35 2.6 2.6 C - PK A,K 8/8/1 
36 2.3 2.3 - Y PK A 4/1/0.5 
37 1.6 - - No - A,K 4/2/1 
38 2.3 2.0 P No - - 4/8/2 
39 0.2 0 C No - N 4/4/2 
40 2.3 0.5 C No PK A,K 8/8/4 
41 2.6 2.6 C Y PK A,K 4/8/1 
Totals/ 
Means 
1.9±0.88 1.6±0.96 29 C 
4 P 
7 Yes 
27 No 
22 
PK 
See text See table 3 
Legend: BCVA are expressed in LogMAR; C= in the central 6mm of the cornea; 
P=peripheral; N=Natamycin; A=Amphotericin; K=Ketoconazole; F=Fluconazole; Y=yes; 
PK=penetrating keratoplasty 
 
 
 
Table 3.  Voriconazole, Natamycin and Amphotericin B MIC90’s, medians and ranges 
(ug/ml). 
 Voriconazole 
(n=35) 
Natamycin (n=35) Amphotericin B 
(n=35) 
MIC90  16 8 2 
Median 8 4 1 
Range 1-16 0.25-16 0.03-4 
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Table 4. Association between antifungals’ mean MIC values and PK necessity. 
 No PK 
necessary 
PK 
necessary 
p-value* 
Natamycin 3.21 (2.68) 6.21 (3.27) 0.005 
Voriconazole 8.93 (4.06) 7.05 (4.53) 0.116 
Amphotericin 0.74 (0.63) 1.48 (1.81) 0.183 
*Mann-Whitney Test 
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4. RESULTADOS 
 
Além dos 3 artigos já publicados, um quarto artigo está em finalização, comparando 
os dados de todos os isolados de ceratites por Fusarium dos estudos no Brasil e EUA. Os 
resultados encontram-se descritos abaixo. 
 
4.1. COMPARAÇÃO FINAL ENTRE BRASIL E ESTADOS UNIDOS 
 
4.1.1. Identificação 
A identificação morfológica dos organismos ao nível de gênero levou em média 5.8 
dias no Brasil, variando de 2 a 14 dias, e 3.6 dias nos EUA, variando de 2 a 12 dias. A 
identificação ao nível de espécie (solani, oxysporum, etc) demorou em média 4 dias, após 
a identificação do organismo pertencendo ao gênero Fusarium em ambos os países. 
Morfologicamente, os organismos foram identificados no Brasil como 35 F. solani, 4 
F. oxysporum e 2 F. dimerum; nos EUA, a identificação foi de 28 Fusarium spp, 19 F. 
oxysporum e 11 F. solani. 
A genotipagem das cepas a partir de culturas puras, demorou em média 1 dia no 
estudo brasileiro, incluindo o tempo para a extração do DNA, PCR, sequenciamento, 
edição e análise das sequências. Nos EUA o tempo médio foi de 3 dias, devido ao fato do 
sequenciamento ter sido feito em um laboratório terceirizado localizado em outro Estado.  
Baseado em genótipos, os 41 isolados do Brasil foram classificados em 3 
complexos de espécies: F. solani species complex (FSSC) 36 isolados (88%), F. 
oxysporum species complex (FOSC) 2 isolados (5%), F. dimerum species complex 
(FDSC) 1 isolado (2%) e 2 isolados não agruparam em nenhum complexo de espécies. 
Os 58 isolados dos EUA foram classificados genotipicamente como: F. solani (FSSC) 44 
isolados (75%), F. oxysporum (FOSC) 9 isolados (16%), F. incarnatum-equiseti (FIESC) 3 
isolados (5%), F. dimerum (FDSC) 1 isolado (2%) e 1 isolado não agrupou em nenhum 
complexo de espécies.  
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4.1.2. Epidemiologia e características clínicas 
 No Brasil, os 41 isolados foram obtidos de 41 olhos de 41 pacientes com ceratite 
por Fusarium spp. Nos EUA, os 58 isolados foram obtidos de 52 pacientes: 40 raspados 
de córnea, 11 lentes de contato (LC), 3 estojos de LC, 3 punções de câmara anterior e 1 
punção vítrea. Seis pacientes tiveram 2 amostras coletadas; um paciente com 2 raspados 
de córnea; um paciente com 2 punções de câmara anterior; dois pacientes com 1 amostra 
corneana e 1 de LC; e dois pacientes com 1 amostra de LC e 1 de estojo de LC. Nos 
casos de pacientes com amostras positivas apenas provenientes de LC e/ou estojo de LC, 
o diagnóstico de ceratite foi considerado positivo para Fusarium se a microscopia confocal 
mostrasse hifas com diâmetro de 5-10um e ramificações em um ângulo de 90o (típicas de 
Fusarium spp) no estroma corneano. A epidemiologia e características clínicas dos 
pacientes, com a respectiva análise estatística, são demonstradas na tabela 1.  
O tempo de acompanhamento no Brasil foi em média de 9.3 meses, variando de 1 
a 24 meses; nos EUA foi de 7.3 meses, variando de 15 dias a 24 meses. O tempo para 
diagnóstico, definido como o intervalo do início dos sintomas até o diagnóstico específico, 
variou de 3 a 90 dias, com média de 19±12 dias no Brasil; nos EUA, variou de 1 a 35 dias, 
com 10±7 dias em média. Em relação à localização dos infiltrados, eles se encontravam 
nos 6mm centrais da córnea em 29 (88%) dos 33 casos em que esta informação 
encontrava-se disponível no Brasil e em 36 (72%) de 50 casos com informação disponível 
nos EUA. 
 No Brasil foram encontrados 29 fatores de risco em 27 pacientes (2 pacientes 
tinham mais de um fator de risco), sendo trauma o mais freqüente. Nos EUA fatores de 
risco foram encontrados em 49 pacientes, sendo o uso de LC o mais freqüente. Os fatores 
de risco encontram-se detalhados na figura 1. 
 O atraso para início do tratamento e tempo para cura versus AV final no Brasil e 
EUA são demonstrados nas figura 2 e 3. 
 No estudo americano, a natamicina foi utilizada em combinação com azóis em 11 
pacientes. Oito destes (73%) necessitaram de ceratoplastia de urgência ou tiveram AV 
final < 20/400, resultado muito pior do que a média dos pacientes. No Brasil, os casos de 
combinação de natamicina com azóis não evidenciaram resultado pior que a média dos 
pacientes.  
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 Nos EUA, 9 pacientes (19%) tiveram uma AV final <20/200; no Brasil 25 pacientes 
(66%) tiveram este resultado. Destes pacientes, 6 casos (67%) foram submetidos a 
ceratoplastia de urgência nos EUA e 20 casos (80%) no Brasil. 
 
 
4.1.3. Teste de sensibilidade in vitro a antifúngicos 
As concentrações inibitórias mínimas para 90% das amostras (MIC90), são 
mostrados na figura 4. A anfotericina B teve os menores valores de MIC90 tanto no Brasil 
como nos EUA. Voriconazol teve os maiores valores em ambos países. 
  
 
4.1.4. Comentários finais 
 As ceratites por Fusarium no Brasil apresentaram piores resultados que as 
ocorridas nos EUA. Os principais fatores de risco e resultados que poderiam explicar este 
pior prognóstico no Brasil seriam: 1) um maior atraso no início do tratamento (19 vs 10 
dias); 2) cepas com maior resistência a natamicina (8 vs 4 ug/ml); 3) maior frequência de 
F. solani (88% vs 75%), a qual tem demonstrado ser a espécie com maior potencial 
patogênico do gênero Fusarium; 4) maior frequência de trauma como fator de risco (50 vs 
18%), com o potencial de inocular o organismo mais profundamente na córnea; 5) maior 
incidência de infiltrados centrais (88% vs 72%) ocasionando pior acuidade visual. 
 Apesar de terem sido testados modelos de regressão logística, não se conseguiu 
evidenciar quais fatores de risco tem maior influência para causar um pior prognóstico.  
 No Brasil, um maior esclarecimento da população, dos médicos generalistas e de 
oftalmologistas em geral, quanto ao reconhecimento e encaminhamento precoce de casos 
com maior potencial de mau prognóstico, além da melhor capacitação de microbiologistas 
na área oftalmológica e uso de métodos diagnósticos baseados em biologia molecular, 
podem ajudar a reduzir o atraso para o diagnóstico e início do tratamento adequado. Além 
disto, uma maior ênfase no uso de equipamentos de uso individual, especialmente nos 
setores da agricultura, jardinagem e construção civil, pode reduzir a incidência de traumas 
oculares, e por consequência, a quantidade de ceratites infecciosas de maior gravidade, 
como é o caso das ceratites causadas pelo gênero Fusarium. 
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Tabela 1. Epidemiologia e características clínicas dos casos de ceratite por Fusarium spp 
nos EUA e Brasil. 
 EUA(n=50) Brasil (n=41) p 
Masculino 22 (44%) 34 (83%) Sexo 
Feminino 28 (56%) 7 (17%) 
0.0001*  
Idade (média (DP)) 39 (19) 45 (15) 0.08** 
Uso de LC 33 (66%) 2 (5%) 0.0001*  
Trauma 9 (18%) 20 (50%) 0.0001*  
Localização dos infiltrados   
Central (6mm centrais) 36 (72%) 36 (88%) 
Periférico 14 (28%) 5 (29%) 
 
0.11* 
Atraso para início do 
tratamento (dias) 
9.7 (7)  
(range: 0-35) 
18.8 (12) 
(range: 0-35) 
0.0004*** 
Tempo para cura (dias) 60 
(variação: 10-100) 
107 
(variação:15-270) 
0.0012*** 
AV inicial LogMAR 
(Snellen) 
0.83 (20/135) 
(variação:20/20-PL) 
1.90 (20/1600) 
(variação: 20/20-PL) 
0.00001*** 
AV final LogMAR 
(Snellen) 
0.65 (20/90) 
(variação:20/20-PL) 
1.60 (20/800) 
(variação: 20/20-MM) 
0.00001*** 
Ceratoplastia de urgência 7 (14%) 22 (54%) 0.0001**** 
AV final <20/200 9 (19%) 25 (66%) 0.0001* 
Atraso para início do tratamento= prazo do início dos sintomas até o início do tratamento específico. 
Tempo para cura= duração do tratamento necessário para eliminar a evidência de infecçào clinicamente 
ativa.  
PL= percepção luminosa; MM= movimento de mãos (vultos) 
* Fisher’s exact test 
** t-test 
*** Mann-Whitney test 
**** Pearson Chi2 
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Figura 1. Fatores de risco das ceratites por Fusarium spp no Brasil e EUA. 
 
 
 
Figura 2. Atraso para tratamento vs acuidade visual final das ceratites por Fusarium spp 
no Brasil e EUA. 
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Figura 3. Tempo para cura vs acuidade visual final no Brasil e EUA. 
 
 
 
Figura 4. MIC90 de Voriconazol, Natamicina e Anfotericina B no Brasil e EUA. 
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5. ANEXOS 
 
5.1 Aprovação do Comitê de Ética em Pesquisa 
 
 
 83 
 
 
 
 
 
 84 
6. REFERÊNCIAS 
 
1. Chang DC, Grant GB, O'Donnell K, et al. Multistate outbreak of Fusarium keratitis 
associated with use of a contact lens solution. JAMA 2006;296:953-963. 
 
2. Xie L, Hu J, Shi W. Treatment failure after lamellar keratoplasty for fungal keratitis. 
Ophthalmology 2008;115:33-36. 
 
3. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull 
World Health Organ 2001;79:214-221. 
 
4. Xie L, Zhong W, Shi W, et al. Spectrum of fungal keratitis in north China. Ophthalmology 
2006;113:1943-1948. 
 
5. Rosa RH, Jr., Miller D, Alfonso EC. The changing spectrum of fungal keratitis in south 
Florida. Ophthalmology 1994;101:1005-1013. 
 
6. Godoy P, Cano J, Gene J, et al. Genotyping of 44 isolates of Fusarium solani, the main 
agent of fungal keratitis in Brazil. J Clin Microbiol 2004;42:4494-4497. 
 
7. Chowdhary A, Singh K. Spectrum of fungal keratitis in North India. Cornea 2005;24:8-
15. 
 
8. Garg P, Gopinathan U, Choudhary K, et al. Keratomycosis: clinical and microbiologic 
experience with dematiaceous fungi. Ophthalmology 2000;107:574-580. 
 
9. Gower EW, Keay LJ, Oechsler RA, et al. Trends in fungal keratitis in the United States, 
2001 to 2007. Ophthalmology 2010;117:2263-2267. 
 
10. Pérez-Balbuena AL, Vanzzini-Rosano V, Valadéz-Virgen Jde J, et al. Fusarium 
keratitis in Mexico. Cornea 2009;28:626-630. 
 85 
 
11. Tanure MA, Cohen EJ, Sudesh S, et al. Spectrum of fungal keratitis at Wills Eye 
Hospital, Philadelphia, Pennsylvania. Cornea 2000;19:307-312. 
 
12. Hofling-Lima AL, Forseto A, Duprat JP, et al. Laboratory study of the mycotic infectious 
eye diseases and factors associated with keratitis. Arq Bras Oftalmol 2005;68:21-27. 
 
13. Jurkunas U, Behlau I, Colby K. Fungal keratitis: changing pathogens and risk factors. 
Cornea 2009;28:638-643. 
 
14. Wykoff CC, Flynn HW, Jr., Miller D, et al. Exogenous fungal endophthalmitis: 
microbiology and clinical outcomes. Ophthalmology 2008;115:1501-1507. 
 
15. Furlanetto RL, Andreo EG, Finotti IG, et al. Epidemiology and etiologic diagnosis of 
infectious keratitis in Uberlandia, Brazil. Eur J Ophthalmol. 2010;20(3):498-503. 
 
16. Cariello AJ, Passos RM, Yu MC, et al. Microbial keratitis at a referral center in Brazil. 
Int Ophthalmol. 2011;31(3):197-204. 
 
17. Ibrahim MM, Vanini R, Ibrahim FM, et al. Epidemiologic aspects and clinical outcome 
of fungal keratitis in southeastern Brazil. Eur J Ophthalmol. 2009;19(3):355-361. 
 
18. O'Donnell K, Sarver BA, Brandt M, et al. Phylogenetic diversity and microsphere array-
based genotyping of human pathogenic Fusaria, including isolates from the multistate 
contact lens-associated U.S. keratitis outbreaks of 2005 and 2006. J Clin Microbiol. 
2007;45:2235-2248. 
 
19. Oechsler RA, Feilmeier MR, Ledee D, et al. Utility of Molecular Sequence Analysis of 
the ITS rRNA Region for Identification of Fusarium spp from Ocular Sources. Invest 
Ophthalmol Vis Sci. 2009;50:2230-2236. 
 
 86 
20. Hsiao CR, Huang L, Bouchara JP, et al. Identification of medically important molds by 
an oligonucleotide array. J Clin Microbiol 2005;43:3760-3768. 
 
21. O'Donnell K, Kistler HC, Tacke BK, et al. Gene genealogies reveal global 
phylogeographic structure and reproductive isolation among lineages of Fusarium 
graminearum, the fungus causing wheat scab. Proc Natl Acad Sci USA 2000;97:7905-
7910. 
 
22. O'Donnell K, Sutton DA, Rinaldi MG, et al. Genetic diversity of human pathogenic 
members of the Fusarium oxysporum complex inferred from multilocus DNA sequence 
data and amplified fragment length polymorphism analyses: evidence for the recent 
dispersion of a geographically widespread clonal lineage and nosocomial origin. J Clin 
Microbiol 2004;42:5109-5120. 
 
23. Zhang N, O'Donnell K, Sutton DA, et al. Members of the Fusarium solani species 
complex that cause infections in both humans and plants are common in the environment. 
J Clin Microbiol 2006;44:2186-2190. 
 
24. Alfonso EC. Genotypic identification of Fusarium species from ocular sources: 
comparison to morphologic classification and antifungal sensitivity testing (an AOS thesis). 
Trans Am Ophthalmol Soc 2008;106:227-239. 
 
25. He D, Hao J, Zhang B, et al. Pathogenic spectrum of fungal keratitis and specific 
identification of Fusarium solani. Invest Ophthalmol Vis Sci 2011;52:2804-2808. 
 
26. Arikan S, Lozano-Chiu M, Paetznick V, et al. Microdilution susceptibility testing of 
amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and 
Fusarium species. J Clin Microbiol 1999;37:3946-3951. 
 
 87 
27. Dotis J, Simitsopoulou M, Dalakiouridou M, et al. Amphotericin B formulations variably 
enhance antifungal activity of human neutrophils and monocytes against Fusarium solani: 
comparison with Aspergillus fumigatus. J Antimicrob Chemother 2008;61:810-817. 
 
28. Lewis RE, Wiederhold NP, Klepser ME. In vitro pharmacodynamics of amphotericin B, 
itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. 
Antimicrob Agents Chemother 2005;49:945-951. 
 
29. Azor M, Gene J, Cano J, et al. Universal in vitro antifungal resistance of genetic clades 
of the Fusarium solani species complex. Antimicrob Agents Chemother 2007;51:1500-
1503. 
 
30. O'Donnell K, Sutton DA, Fothergill A, et al. Molecular phylogenetic diversity, multilocus 
haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani 
species complex. J Clin Microbiol 2008;46:2477-2490. 
 
31. Alfonso EC, Cantu-Dibildox J, Munir WM, et al. Insurgence of Fusarium keratitis 
associated with contact lens wear. Arch Ophthalmol 2006;124:941-947. 
 
32. Liesegang TJ, Forster RK. Spectrum of microbial keratitis in South Florida. Am J 
Ophthalmol 1980;90:38-47. 
 
33. Scott IU, Schein OD, West S, et al. Functional status and quality of life measurement 
among ophthalmic patients. Arch Ophthalmol 1994;112:329-335. 
 
34. Chen A, Prajna L, Srinivasan M, et al. Does in vitro susceptibility predict clinical 
outcome in bacterial keratitis? Am J Ophthalmol. 2008;145(3):409-412. 
 
35. Lalitha P, Srinivasan M, Manikandan P, et al. Relationship of in vitro susceptibility to 
moxifloxacin and in vivo clinical outcome in bacterial keratitis. Clin Infect Dis. 
2012;54(10):1381-1387. 
 88 
 
36. Kaye S, Tuft S, Neal T, et al. Bacterial susceptibility to topical antimicrobials and 
clinical outcome in bacterial keratitis. Invest Ophthalmol Vis Sci. 2010;51(1):362-368. 
 
37. Pradhan L, Sharma S, Nalamada S, et al. Natamycin in the treatment of 
keratomycosis: correlation of treatment outcome and in vitro susceptibility of fungal 
isolates. Indian J Ophthalmol. 2011;59:512-514. 
 
38. Lalitha P, Prajna NV, Oldenburg CE, Srinivasan M, Krishnan T, Mascarenhas J et al. 
Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical 
trial. Cornea 2012; 31(6):662-7. 
 
39. Shapiro BL, Lalitha P, Loh AR, et al. Susceptibility testing and clinical outcome in 
fungal keratitis. Br J Ophthalmol. 2010;94(3):384-385. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
 
 
The aims of this study are: 
1) To study and compare the phylogenetic diversity of strains of Fusarium spp isolated 
from cases of infectious keratitis in South Florida - United States of America (USA) through 
identification by genotyping and microbiological phenotypical analysis; 
 2) To analyze the Fusarium species isolated from keratitis in South Florida – USA 
identified by genotyping, their antifungal in vitro susceptibility profiles and patients’ clinical 
outcomes; 
3) To study and compare the phylogenetic diversity of Fusarium spp strains isolated from 
cases of infectious keratitis in Brazil, identified by genotyping and microbiological 
phenotypical analysis, the results of antifungal in vitro susceptibility tests and the patients’ 
clinical outcomes; 
4) Comparison of the identification data of Fusarium spp strains from patients with 
infectious keratitis in the U.S. and Brazil, evaluating also the antifungal in vitro 
susceptibility profiles and the clinical outcomes of the studied patients. 
 
For the identification of the Fusarium keratitis strains in the USA and in Brazil, DNA 
sequence analysis from the Internal Transcribed Spacer (ITS) region was used, as well as 
the microbiology morphological classification, using the macro and microscopic study of 
the strains. Broth microdilution tests were performed to obtain the strains’ in vitro 
susceptibility profiles of the antifungals natamycin, amphotericin B and voriconazole. The 
medical records of the respective patients were analyzed and their clinical outcomes 
compared with the genotyping and antifungal in vitro susceptibility results. 
In the U.S. 58 keratitis isolates were classified by genotyping into: Fusarium solani 
(75%), F. oxysporum (16%), F. incarnatum-equiseti (5%), F. dimerum (2%) and Fusarium 
spp (2%) which was not classified into any complex species. Isolates of F. solani had 
voriconazole MIC90 values significantly higher than F. non-solani (16 and 4ug/ml, 
respectively). Patients with F. solani isolates also exhibited a longer time to cure (65 vs. 40 
days), a worse final visual acuity mean (20/118 vs 20/36), and a higher need for 
 therapeutic keratoplasty (7 vs 0 surgeries) when compared to patients which had infections 
caused by F. non-solani. The use of contact lenses was the most common risk factor 
among the patients in this study (66%). 
In Brazil, 41 keratitis isolates were classified genotypically in: F. solani (88%), F. 
oxysporum (5%), F. dimerum (2%) and two Fusarium spp (5%) which were not classified 
into any species complex. The treatment delay was in average19 days and the mean time 
to cure was 107 days. Final visual acuities ranged from 20/20 to light perception and 
averaged 20/800 (LogMAR 1.6). History of trauma was the most frequent risk factor, being 
present in 20 patients (50%). Therapeutic keratoplasty was required in 22 patients (54%). 
Amphotericin B had the lowest MIC90 values (2ug/ml) in Brazil and USA. 
Voriconazole had the highest values (16ug/ml) in both countries. The isolates were slightly 
more resistant to natamycin in Brazil (8 vs 4 ug/ml in the U.S.), and there was also in this 
country an association between strains with higher MIC for natamycin and greater need for 
therapeutic keratoplasty. 
By comparing the results of identification, antifungal susceptibility and clinical 
outcomes from Fusarium keratitis cases in the U.S. and in Brazil, it is possible to conclude 
that: the initial and final visual acuities were worse in Brazil; a greater number of men and 
trauma were present in the Brazilian study instead of women and contact lens (CL) use in 
the U.S.; a larger number of therapeutic keratoplasties were necessary in Brazil; and a 
longer time for diagnosis and cure were found in Brazil. 
!
